

## PERSONAL INFORMATION

## Francesca Maria Gay

 20, Corso Marconi - 10125 Turin (Italy) 00390116334279 (work)  00393468853667 (personal) [fgay@cittadellasalute.to.it](mailto:fgay@cittadellasalute.to.it) (work)[francesca.gay@unito.it](mailto:francesca.gay@unito.it) (work)

Sex F | Date of birth September 10, 1979 | Nationality Italian

CF: GYAFNC79P50L219K

## CURRENT POSITION

Associate Professor, Department of Molecular Biotechnology and Health Science, University of Torino, "SC Ematologia 1" Division, at AOU Città della Salute e della Scienza, Turin, Italy


## STUDIES AND TITLES

Medical Doctor (2004)

Hematologist (2008)

PhD in Medicine and Experimental Therapy (2014)

## WORK EXPERIENCE



December 2019-to date

Associate Professor, Department of Molecular Biotechnology and Health Science, University of Torino, "SC Ematologia 1" Division, at AOU Città della Salute e della Scienza, Turin, Italy

December 2010-December 2019

1st Level Head Physician at the "SC Ematologia 1" Division, at AOU Città della Salute e della Scienza, Turin, Italy.


October 2009-November 2010

Clinical research and assistance to multiple myeloma patients, at the "SC Ematologia 1" Division, at AOU Città della Salute e della Scienza, Turin, Italy

February 2009-September 2009

Clinical research at Mayo Clinic College of Medicine, Department of Internal Medicine, Division of Hematology, Rochester, MN, USA

## EDUCATION AND TRAINING



January 2011-December 2014

PhD in Medicine and Experimental Therapy  
Università degli Studi di Torino (UNITO), Turin – Italy

Academic years 2005-2008

Specialization School in Hematology  
Università degli Studi di Torino (UNITO), Turin - Italy  
Hematology specialization obtained on December 23, 2008; final grade: 70/70 cum laude

March 2005

MD license to practice and inclusion into the MD professional registry of Turin - Italy  
On March 7, 2005 (MD professional registry identification number: 20427)


Academic years 1998-2004


Faculty of Medicine and Surgery,  
Università degli Studi di Torino (UNITO), Turin - Italy  
Degree obtained on July 14, 2004; final grade: 110/110 cum laude

September 1993-June 1998

Scientific High School (PNI – mathematics and informatics specialization)  
Scientific High School "Aldo Moro", Rivarolo C.se –Turin, Italy  
High school diploma; final grade: 60/60

## PERSONAL SKILLS





Mother tongue Italian

Other languages

English	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Interaction	Production	
	C1	C1	C1	C1	C1

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user

[Common European Framework of Reference for Languages](#)

Job-related skills

- Clinical research skills, in particular in the field of multiple myeloma, working with the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) and the European Myeloma Network (EMN).
- Scientific activities for the diagnosis and treatment of myeloma patients using new biological molecules and/or monoclonal antibodies; participation in various national and international clinical trials about lymph-proliferative and plasma cell disorders (Phase I, II, III)
- Participation in - and organization of - inter-divisional groups (GIC) to discuss complex clinical cases regarding patients with multiple myeloma, plasma cell leukemia, and amyloidosis.
- Activities as hematology specialist, including diagnosis and treatment of hematologic patients, in particular those with lymph-proliferative and plasma cell disorders; outpatient activities and diagnostic assessment (including bone biopsies and marrow aspirates), as well as therapeutic and follow-up evaluation of patients, including bureaucratic matters; day hospital activities, including defining chemotherapy cycles and treatment schedules; clinical evaluation of onco-hematologic patients, assessment of test results in terms of remission and adverse events; consulting activities; inter-divisional doctor on call.
- Teaching activities to - and supervision of - medical students, as well as residents and fellows, during their internship/training period (outpatient, day hospital and care unit).
- Teaching activities school of Medicine and school of Biotechnology, University of Turin.


Driving License B

## ADDITIONAL INFORMATION

Publications	<p>134 publications on national and international journals – Scopus H-index 38. (Complete list-Attachment A) plus 3 Book Chapter</p> <p>Reviewer for different international, scientific journals (such as Lancet, Lancet Oncology, Blood, Leukemia, Lancet Hematology, Clinical cancer research, Blood Cancer Journal, Plos One, Cancer, HemaSphere, Hematologica, Oncotarget, Journal of Cancer, Annals of Hematology, Expert Opinion on Pharmacotherapy, American Journal of Hematology, Advances in Cell and Gene therapies, European Journal of Hematology, British journal of hematology, Clinical Lymphoma, Myeloma and Leukemia, Oncotargets and Therapy, Cancer Management and Research, Journal of Oncology, Expert Review on Proteomics, Transfusion and Apheresis Science).</p>
Presentations	<p>Speaker/Chair in different congresses/seminars, including oral presentations at national and international congresses (complete list -Attachments B and C)</p> <p>Reviewer to select abstract at the following congresses: International Myeloma Workshop (2015, 2017,2019); European Hematology Association (2013, 2016, 2020, 2021,2022); American Society of Hematology (2011, 2012, 2019, 2020- Educational papers and chair), European Bone Marrow Transplant (2022)</p>
Grant Support participation	<p>Participant in the project “Minimal residual disease to better characterize multiple myeloma response and detect early relapse”, for the grant “Multiple Myeloma Research Foundation - MMRF 2010”.</p> <p>Bart Barlogie Young Investigation Award, Grant from IMS (sept 2019)</p> <p>“Otto Kahler award” for long-term cooperation with Czech Myeloma Group. (sept 2020)</p>
Professional societies	<p>EHA, EMN, IMS, ASH, SIE, ESMO</p> <p>Member of the EHA SPC advisory board (2019-2021)</p> <p>Member of the Educational committee of IMS (2020) and of the IMS Board (2021-2023)</p> <p>Member of the EMN Young Board</p> <p>Member of the ESMO Clinical Practice Guidelines committee (2021-22)</p> <p>Member of the EHA SPC advisory board (2021-2022)</p> <p>Member of the GIMEMA Working Party on Immune therapies</p>
Meetings/Seminars/Courses	<p>Participation in several meetings, seminars and courses (Complete list in attachment C)</p> <p>Member of the congress secretariat of EMN 2018 and EMN 2020-21 meetings</p> <p>Member of the scientific secretary of the EMN Master on Multiple Myeloma 1 level 2019-2020 , 2020-2021, 2021-2022</p>
Clinical Trial Experience	<p>Experience in studies of phase I, II, III concerning Multiple Myeloma as principal investigator, subinvestigator, medical monitor, member of DSMC</p>
ICH-GCP Training	<p>ICH-GCP training attended for previous clinical trials</p> <p>GCP certification</p>
Scientific interests	<p>Multiple Myeloma</p> <ul style="list-style-type: none"> <li>- efficacy of high-dose versus conventional chemotherapy</li> <li>- role of prognostic factors</li> <li>- immunosurveillance and immunotherapy</li> <li>- molecular alterations and minimal residual disease</li> </ul>

Turin, Apr 7, 2022

Dr. Francesca Gay



## Attachment A: Publications

1. Hofste Op Bruinink D, Kuiper R, van Duin M, .. **Gay F.** .. Sonneveld P. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. J Clin Oncol. 2022 Mar 31;JCO2101217. doi: 10.1200/JCO.21.01217. Online ahead of print.PMID: 35357885
- 2.
3. Mateos MV, Weisel K, De Stefano V, ... **Gay F.** .. Moreau P. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022 Mar 24. doi: 10.1038/s41375-022-01531-2. Online ahead of print.PMID: 35332278
4. Dhakal B, Shah N, Kansagra A, ... **Gay F.** .. Kumar S. ASTCT Clinical Practice recommendations for transplant and cellular therapies in multiple myeloma. Transplant Cell Ther. 2022 Mar 16:S2666-6367(22)01166-6. doi: 10.1016/j.jtct.2022.03.019. Online ahead of print. PMID: 35306217
5. **Gay F.** Musto P, Rota-Scalabrini D et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021 Nov 11:S1470-2045(21)00535-0. doi: 10.1016/S1470-2045(21)00535-0. Online ahead of print. PMID: 34774221
6. Ludwig H, Sonneveld P, Facon T, ... **Gay F.** .. Terpos E. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021 Oct 28:S2352-3026(21)00278-7. doi: 10.1016/S2352-3026(21)00278-7. Online ahead of print. PMID: 34756169
7. Sonneveld P, Dimopoulos MA, Beksac M, ... **Gay F.** .. Cavo M. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma J Clin Oncol. 2021 Nov 10;39(32):3613-3622. doi: 10.1200/JCO.21.01045. Epub 2021 Sep 14. PMID: 34520219
8. Mina R, **Gay F.** The role of autologous stem-cell transplantation in multiple myeloma in 2021. Curr Opin Oncol. 2021 Nov 1;33(6):642-647. doi: 10.1097/CCO.0000000000000783. PMID: 34419954
9. Anderson KC, Auclair D, Adam SJ .... **Gay F.** ... Kumar SK Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clin Cancer Res. 2021 Jul 28;clincanres.1059.2021. doi: 10.1158/1078-0432.CCR-21-1059. Online ahead of print. PMID: 34321279
10. Musto P, Engelhardt M, Caers J, .. **Gay F.** .. Miguel JS. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica. 2021 Nov 1;106(11):2799-2812. doi: 10.3324/haematol.2021.278519. PMID: 34261295
11. **Gay F.** Günther A, Offidani M, et al Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. Cancer. 2021 Sep 15;127(18):3413-3421. doi: 10.1002/cncr.33647. Epub 2021 Jun 28. PMID: 34181755
12. Holstein SA, Bahlis N, Bergsagel PL, ... **Gay F.** .. McCarthy PL. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplant Cell Ther. 2021 Oct;27(10):807-816. doi: 10.1016/j.jtct.2021.05.027. Epub 2021 Jun 6. PMID: 34107340
13. Oliva S, Bruinink DHO, Rihova L, ... **Gay F.** ... Sonneveld P. **Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.** Blood Cancer J. 2021 Jun 3;11(6):106. doi: 10.1038/s41408-021-00498-0. PMID: 34083504
14. Nathwani N, Bertamini L, .. **Gay F.** .. Krishnan A. When and How to Treat Relapsed Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2021 Mar;41:358-375. doi: 10.1200/EDBK\_320129. PMID: 34010043

15. Mingrone G, Astarita A, Airale L, ..**Gay F**, .. Milan A. Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients. *Front Cardiovasc Med*. 2021 Apr 21;8:645678. doi: 10.3389/fcvm.2021.645678. eCollection 2021. PMID: 33969010
16. Bertamini L, D'Agostino M, **Gay F**. MRD Assessment in Multiple Myeloma: Progress and Challenges. *Curr Hematol Malig Rep*. 2021 Apr;16(2):162-171. doi: 10.1007/s11899-021-00633-5. Epub 2021 May 5. PMID: 33950462
17. Zaccaria GM, Bertamini L, Petrucci MT, ...**Gay F**. Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. *Clin Cancer Res*. 2021 Apr 29. doi: 10.1158/1078-0432.CCR-21-0134. Online ahead of print. PMID: 33926915
18. Astarita A, Mingrone G, Airale L, ... **Gay F**, .. Milan A. Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction. *Cancers (Basel)*. 2021 Apr 1;13(7):1631. doi: 10.3390/cancers13071631. PMID: 33915804
19. Ramasamy K, **Gay F**, Weisel K, .. Richardson PG **Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options**. *Blood Rev*. 2021 Feb 9:100808. doi: 10.1016/j.blre.2021.100808. PMID: 33863601
20. Bruno B, Wäsch R, Engelhardt M, **Gay F**, ..., Boccadoro M. European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. *Haematologica*. 2021 Apr 1. doi: 10.3324/haematol.2020.276402. PMID: 33792221
21. Rosiñol L, Beksac M, Zamagni E, ... **Gay F**, ... Bladé J. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. *Br J Haematol*. 2021 Mar 16. doi: 10.1111/bjh.17338. PMID: 33724461
22. Moreau P, Kumar SK, San Miguel J, ...**Gay F**, ....., Rajkumar SV, Dimopoulos MA, Richardson PG. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group *Lancet Oncol*. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7. PMID: 33662288 [IF]: 33,752
23. Chari A, Samur MK, Martinez-Lopez J, ... **Gay F**, ... San Miguel J, Munshi NC, Avet-Loiseau H. Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset. *Blood*. 2020 Nov 6;blood.2020008150. doi: 10.1182/blood.2020008150. Online ahead of print. PMID: 33156904 [IF]: 17,543
24. Zamagni E, Nanni C, ... **Gay F**, ... Bodet-Milin C, Moreau P, Kraeber-Bodéré F. Standardization of (18)F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. *J Clin Oncol*. 2020 Nov 5;JCO2000386. doi: 10.1200/JCO.20.00386. Online ahead of print. PMID: 33151787 [IF]: 32,956
25. van de Donk NWCJ, Kastiris E, **Gay F**. Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches. *Front Oncol*. 2020 Oct 6;10:607571. doi:10.3389/fonc.2020.607571. eCollection 2020. PMID: 33123490 Free PMC article [IF]: 4,416
26. Mina R, Bonello F, **Gay F**, Zamagni E, Boccadoro M. Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report. *Clin Lymphoma Myeloma Leuk*. 2020 Sep 17:S2152-2650(20)30506-1. doi: 10.1016/j.clml.2020.08.019. Online ahead of print. PMID: 33121894 [IF]: 2,298
27. Weisel K, Mateos MV, **Gay F**, ... Moreau P. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. *Leukemia*. 2020 Oct 16. doi: 10.1038/s41375-020-01049-5. Online ahead of print. PMID: 33067574 Free article. [IF]: 8,665
28. Mateos MV, Bladé J, ... **Gay F**, Sonneveld P, Gullbo J, Richardson PG. Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. *J Clin Med*. 2020 Sep 27;9(10):3120. doi: 10.3390/jcm9103120. PMID: 32992506 Free PMC article. Review. [IF]: 2,046

29. Ludwig H, Boccadoro M, Moreau P, ... **Gay F** .... Abildgaard N, Bringhen S, Sonneveld P. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. *Leukemia*. 2020 Aug 19. doi: 10.1038/s41375-020-01016-0. Online ahead of print. PMID: 32814840 Review. [IF]: 8,665.
30. Costa LJ, Derman BA, Bal S, .....Kumar S, **Gay F**, Paiva B. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. *Leukemia*. 2020 Aug 11. doi: 10.1038/s41375-020-01012-4. Online ahead of print. PMID: 32778736 Free article. Review. [IF]: 8,665.
31. Bertamini L, **Gay F**. Checkpoint inhibitors and myeloma: promises, deadlocks and new directions. *Ann Transl Med*. 2020 Jun;8(12):777. doi: 10.21037/atm.2020.02.65. PMID: 32647702 Free PMC article. [IF]: 3,297.
32. D'Agostino M, Zaccaria GM, Ziccheddu B, .... **Gay F**. Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing. *Clin Cancer Res*. 2020 Sep 15;26(18):4832-4841. doi: 10.1158/1078-0432.CCR-20-0951. Epub 2020 Jul 2. PMID: 32616499 [IF]: 10,107.
33. Holstein SA, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, Dhodapkar MV, **Gay F**, .... McCarthy PL. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. *Biol Blood Marrow Transplant*. 2020 Oct;26(10):e247-e255. doi: 10.1016/j.bbmt.2020.06.011. Epub 2020 Jun 24. PMID: 32589921 [IF]: 3,670
34. Terpos E, Engelhardt M, Cook G, **Gay F**, et al Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). *Leukemia*. 2020 May 22;1-12. doi: 10.1038/s41375-020-0876-z. Online ahead of print. PMID: 32444866 [IF]: 8,665.
35. Cavo M, **Gay F**, et al Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. *Lancet Haematol*. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30. PMID: 32359506 [IF]: 10,409.
36. Mina R, Joseph NS, **Gay F**, et al Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. *Blood Cancer J*. 2020 Apr 14;10(4):40. doi: 10.1038/s41408-020-0307-4. PMID: 32286263 [IF]: 8,023.
37. D'Agostino, M., Mina, R., & **Gay, F.** (2020). Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen? *The Lancet Haematology*. Ahead of print. doi: 10.1016/s2352-3026(19)30254-6 [IF]: 10,409.
38. Bonello, F., Mina, R., Boccadoro, M., & **Gay, F.** (2020, January 1). Therapeutic monoclonal antibodies and antibody products: Current practices and development in multiple myeloma. *Cancers*, Vol. 12. doi: 10.3390/cancers12010015 [IF]: 6,126.
39. Bonello F, Pulini S, Ballanti S, Gentile M, Spada S, Annibali O, ....., **Gay F**. Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. *Cancers (Basel)*. 2019 Nov 5;11(11). pii: E1735. doi: 10.3390/cancers11111735. PMID: 31694338 [IF]: 6,126.
40. Ghisoni E, Marandino L, Lombardi P, Bonzano A, Becco P, ... **Gay F**, Rota Scalabrini D. Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report. *Acta Haematol*. 2019 Sep 25;1-5. doi: 10.1159/000502538. [Epub ahead of print] PMID: 31553985 [IF]: 1,196.
41. Montefusco V., **Gay F.**, Spada S., De Paoli L., Di Raimondo F., Ribolla R., ... Boccadoro M. (2019). Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. *Haematologica*. 2019 Jun 20. pii: haematol.2019.219139. doi: 10.3324/haematol.2019.219139. [IF]: 7,166.
42. Bruno, G., Bringhen, S., Maffei, I., Iannaccone, A., Crea, T., Ravera, A., ..., **Gay, F.**, ... Milan, A. (2019). Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy. *Cancers*, 11(5), 622. https://doi.org/10.3390/cancers11050622. [IF]: 5,326.
43. Plesner, T., Arkenau, H., **Gay, F.**, Minnema, M. C., Boccadoro, M., Moreau, P., ... Richardson, P. G. (2019). Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with



relapsed or relapsed/refractory multiple myeloma (GEN 503): final results of an open-label, phase 1/2 study. *British Journal of Haematology*, bjh.15879. <https://doi.org/10.1111/bjh.15879>. IF 5,128.

44. **Gay, F.** & Mina R. (2019). Redefining the treatment paradigm for multiple myeloma. *The Lancet Oncology*, Epub ahead of print. [https://doi.org/10.1016/S1470-2045\(19\)30295-5](https://doi.org/10.1016/S1470-2045(19)30295-5). IF 36,421.
45. Castella, B., Mina, R., & **Gay, F.** (2019). CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab. *Cytometry Part A*, 95(4), 416–418. <https://doi.org/10.1002/cyto.a.23752>. IF 3,260.
46. **Gay, F.** & Goldschmidt, H. (2019). Do we need cytogenetics in the follow-up of multiple myeloma? *British Journal of Haematology*, 185(3), 399–401. <https://doi.org/10.1111/bjh.15781>. IF 5,128.
47. Bringhen, S., Milan, A., D'Agostino, M., Ferri, C., Wäsch, R., **Gay, F.**, ... Engelhardt, M. (2019). Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. *Journal of Internal Medicine*, joim.12882. <https://doi.org/10.1111/joim.12882>. IF 6,754.
48. Iannaccone, A., Bruno, G., Ravera, A., **Gay, F.**, Salvini, M., Bringhen, S., ... Milan, A. (2018). Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy. *High Blood Pressure & Cardiovascular Prevention*, 25(2), 209–218. <https://doi.org/10.1007/s40292-018-0256-1>. IF 1,76
49. D'Agostino, M., De Paoli, L., Conticello, C., Offidani, M., Ria, R., Petrucci, M. T., ... **Gay, F.** (2018). Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. *Critical Reviews in Oncology/Hematology*, 132, 9–16. <https://doi.org/10.1016/j.critrevonc.2018.09.008>. IF 4,495.
50. **Gay, F.**, Jackson, G., Rosiñol, L., Holstein, S. A., Moreau, P., Spada, S., ... Attal, M. (2018). Maintenance Treatment and Survival in Patients with Myeloma. A Systematic Review and Network Meta-analysis. *JAMA Oncology*, 4(10), 1389–1397. <https://doi.org/10.1001/jamaoncol.2018.2961>. IF 20,871.
51. Dimopoulos, M. A., **Gay, F.**, Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., ... Janakiram, M. (2019). Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. *The Lancet*, 393(10168), 253–264. [https://doi.org/10.1016/S0140-6736\(18\)33003-4](https://doi.org/10.1016/S0140-6736(18)33003-4). IF 53,254.
52. Cerrato, C., Di Raimondo, F., De Paoli, L., Spada, S., Patriarca, F., Crippa, C., ... **Gay, F.** (2018). Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. *Journal of Cancer Research and Clinical Oncology*, 144(7), 1357–1366. <https://doi.org/10.1007/s00432-018-2641-5>. IF 3,282.
53. Nanni, C., Versari, A., Chauvie, S., Bertone, E., Bianchi, A., Rensi, M., ..., **Gay, F.**, ... Zamagni, E. (2018). Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET Use). *European Journal of Nuclear Medicine and Molecular Imaging*, 45(5), 712–719. <https://doi.org/10.1007/s00259-017-3909-8>. IF 7,704.
54. Bonello, F., D'Agostino, M., Moscvin, M., Cerrato, C., Boccadoro, M., & **Gay, F.** (2018). CD38 as an immunotherapeutic target in multiple myeloma. *Expert Opinion on Biological Therapy*, 18(12), 1209–1221. <https://doi.org/10.1080/14712598.2018.1544240>. IF 3,974.
55. **Gay, F.** & Larocca, A. (2018). Special problems in the management of elderly patients with multiple myeloma. *European Journal of Internal Medicine*, 58, 64–69. <https://doi.org/10.1016/j.ejim.2018.05.027>. IF 3,282.
56. Oliva, S., Troia, R., D'Agostino, M., Boccadoro, M., & **Gay, F.** (2018). Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma. *Frontiers in Immunology*, 9. <https://doi.org/10.3389/fimmu.2018.02749>. IF 5,511
57. Bringhen, S., Milan, A., Ferri, C., Wäsch, R., **Gay, F.**, Larocca, A., ... Engelhardt, M. (2018). Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). *Haematologica*, 103(9), 1422–1432. <https://doi.org/10.3324/haematol.2018.191288>. IF 9,090.

58. D'Agostino, M., Gazzera, G., Cetani, G., Brighen, S., Boccadoro, M., & **Gay, F.** (2018). Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. *Current Medicinal Chemistry*, 25. <https://doi.org/10.2174/0929867325666180514114806>. IF 3,460.
59. Leleu, X., **Gay, F.**, Flament, A., Allcott, K., & Delforge, M. (2018). Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate? *Annals of Hematology*, 97(3), 387–400. <https://doi.org/10.1007/s00277-017-3191-7>. IF 2,845.
60. **Gay, F.**, Engelhardt, M., Terpos, E., Wäsch, R., Giaccone, L., Auner, H. W., ... Sonneveld, P. (2018). From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. *Haematologica*, 103(2), 197–211. <https://doi.org/10.3324/haematol.2017.174573>. IF 9,090.
61. Gavriatopoulou, M., Musto, P., Caers, J., Merlini, G., Kastiris, E., van de Donk, N., ..., **Gay, F.**, ... Terpos, E. (2018). European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. *Leukemia*, 32(9), 1883–1898. <https://doi.org/10.1038/s41375-018-0209-7>. IF 10,023.
62. Caers, J., Garderet, L., Kortüm, K. M., O'Dwyer, M. E., van de Donk, N. W. C. J., Binder, M., ..., **Gay, F.**, ... Engelhardt, M. (2018). European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. *Haematologica*, 103(11), 1772–1784. <https://doi.org/10.3324/haematol.2018.189159>. IF 9,090.
63. Larocca, A., Dold, S. M., Zweegman, S., Terpos, E., Wäsch, R., D'Agostino, M., ..., **Gay, F.**, ... Engelhardt, M. (2018). Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). *Leukemia*, 32(8), 1697–1712. <https://doi.org/10.1038/s41375-018-0142-9>. IF 10,023.
64. Ludwig, H., Delforge, M., Facon, T., Einsele, H., **Gay, F.**, Moreau, P., ... Sonneveld, P. (2018). Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. *Leukemia*, 32(7), 1542–1560. <https://doi.org/10.1038/s41375-018-0040-1>. IF 10,023.
65. **Gay, F.**, Oliva, S., Petrucci, M. T., Montefusco, V., Conticello, C., Musto, P., ... Boccadoro, M. (2017). Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. *Leukemia*, 31(8), 1727–1734. <https://doi.org/10.1038/leu.2016.381>. IF 10,023.
66. Offidani, M., Corvatta, L., Brighen, S., Gentili, S., Troia, R., Maracci, L., ..., **Gay, F.**, ... Boccadoro, M. (2017). Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. *EUROPEAN JOURNAL OF HAEMATOLOGY*, 98(3), 289–295. <https://doi.org/10.1111/ejh.12834>. IF 2,594.
67. Oliva, S., Gambella, M., Gilestro, M., Muccio, V. E., **Gay, F.**, Drandi, D., ... Omedè, P. (2017). Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. *Oncotarget*, 8(4), 5924–5935. <https://doi.org/10.18632/oncotarget.12641>. IF 5,168.
68. Gentile, M., Magarotto, V., Offidani, M., Musto, P., Brighen, S., Teresa Petrucci, M., ..., **Gay, F.**, ... Morabito, F. (2017). Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. *American Journal of Hematology*, 92(3), 244–250. <https://doi.org/10.1002/ajh.24621>. IF 5,303.
69. McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., ..., **Gay, F.**, ... Attal, M. (2017). Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology*, 35(29), 3279–3289. <https://doi.org/10.1200/JCO.2017.72.6679>. IF 26,360.
70. Mina, R., D'Agostino, M., Cerrato, C., **Gay, F.**, & Palumbo, A. (2017). Plasma cell leukemia: update on biology and therapy. *LEUKEMIA & LYMPHOMA*, 58(7), 1538–1547. <https://doi.org/10.1080/10428194.2016.1250263>. IF 2,644. Citazioni ricevute: WoS AD 9; WoS CC 9; Sc 8.
71. D'Agostino, M., Salvini, M., Palumbo, A., Larocca, A., & **Gay, F.** (2017). Novel investigational drugs active as single agents in multiple myeloma. *EXPERT OPINION ON INVESTIGATIONAL DRUGS*, 26(6), 699–711. <https://doi.org/10.1080/13543784.2017.1324571>. IF 3,883.



72. Offidani, M., Gentili, S., **Gay, F.**, Aghemo, E., Maracci, L., Corvatta, L., & Palumbo, A. (2017). Stem Cell Transplantation in Multiple Myeloma. *CURRENT CANCER DRUG TARGETS*, 17(9), 769–781. <https://doi.org/10.1174/1568009616666160910090136>. IF 2,626.
73. Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., ..., **Gay, F.**, ... Anderson, K. C. (2017). Multiple myeloma. *NATURE REVIEWS DISEASE PRIMERS*, 3. <https://doi.org/10.1038/nrdp.2017.46>. IF 16,071.
74. Larocca, A., Mina, R., **Gay, F.**, Bringhen, S., ... Boccadoro, M., (2017). Emerging drugs and combinations to treat multiple myeloma. *Oncotarget*, 5(0). <https://doi.org/10.18632/oncotarget.19269>. IF 5,168.
75. **Gay, F.**, D'Agostino, M., Giaccone, L., Genuardi, M., Festuccia, M., Boccadoro, M., & Bruno, B. (2017). Immunologic Approaches: CAR-T Cells and Checkpoint Inhibitors. *Clinical Lymphoma, Myeloma & Leukemia*, 17(8), 471–478. <https://doi.org/10.1016/j.clml.2017.06.014>. IF 2,308.
76. **Gay, F.**, Genuardi, M., & Boccadoro, M. (2017). Autologous transplant for myeloma: when the old meets the new. *ONCOTARGET*, 8(53), 90618–90619. <https://doi.org/10.18632/oncotarget.21605>. IF 5,168.
77. Zamagni, E., Nanni, C., **Gay, F.**, Pezzi, A., Patriarca, F., Bellò, M., ... Cavo, M. (2016). 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. *Leukemia*, 30(2), 417–22. <https://doi.org/10.1038/leu.2015.291>. IF 10,023.
78. Fouquet, G., **Gay, F.**, Boyle, E., Bringhen, S., Larocca, A., Facon, T., ... Palumbo, A. (2016). Treatment of Newly Diagnosed Elderly Multiple Myeloma. *Cancer Treatment and Research*, 169, 123–143. [https://doi.org/10.1007/978-3-319-40320-5\\_8](https://doi.org/10.1007/978-3-319-40320-5_8). IF 6,75
79. Pawlyn, C.,\* **Gay, F.**,\* Larocca, A., Roy, V., & Ailawadhi, S. (2016). Nuances in the Management of Older People With Multiple Myeloma. *CURRENT HEMATOLOGIC MALIGNANCY REPORTS*, 11(3), 241–251. <https://doi.org/10.1007/s11899-016-0323-4> (\*Share the first authorship). IF 2,338.
80. van de Donk, N. W. C. J., Moreau, P., Plesner, T., Palumbo, A., **Gay, F.**, Laubach, J. P., ... Richardson, P. G. (2016). Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. *Blood*, 127(6), 681–695. <https://doi.org/10.1182/blood-2015-10-646810>. IF 15,132.
81. Nanni, C., Zamagni, E., Versari, A., Chauvie, S., Bianchi, A., Rensi, M., ..., **Gay, F.**, ... Fanti, S. (2016). Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USE). *European Journal of Nuclear Medicine and Molecular Imaging*, 43(3), 414–421. <https://doi.org/10.1007/s00259-015-3200-9>. IF 7,704.
82. Musto, P., Simeon, V., Grossi, A., **Gay, F.**, Bringhen, S., Larocca, A., ... Boccadoro, M. (2015). Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. *STEM CELL RESEARCH & THERAPY*, 6. <https://doi.org/10.1186/s13287-015-0033-1>. IF 4,963.
83. Palumbo, A., **Gay, F.**, Cavallo, F., Di Raimondo, F., Larocca, A., Hardan, I., ... Boccadoro, M. (2015). Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 33(30), 3459–66. <https://doi.org/10.1200/JCO.2014.60.2466>. IF 26,360.
84. Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., ..., **Gay, F.**, ... Moreau, P. (2015). Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 33(26), 2863–9. <https://doi.org/10.1200/JCO.2015.61.2267>. IF 26,360.
85. **Gay, F.**, Oliva, S., Petrucci, M. T., Conticello, C., Catalano, L., Corradini, P., ... Palumbo, A. (2015). Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. *The Lancet Oncology*, 16(16), 1617–29. [https://doi.org/10.1016/S1470-2045\(15\)00389-7](https://doi.org/10.1016/S1470-2045(15)00389-7). IF 36,421.

86. **Gay, F.**, Cavallo, F., & Palumbo, A. (2015). The Role of Pre-Transplant Induction Regimens and Autologous Stem Cell Transplantation in the Era of Novel Targeted Agents. *DRUGS*, 75(4), 367–375. <https://doi.org/10.1007/s40265-015-0367-0>. IF 4,690. Citazioni ricevute: WoS AD 3; WoS CC 2; Sc 2.
87. **Gay, F.**, & Palumbo, A. (2015). Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective? *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*, 21(10), 1705–1706. <https://doi.org/10.1016/j.bbmt.2015.08.005>. IF 4,484.
88. Terpos, E., Kleber, M., Engelhardt, M., Zweegman, S., **Gay, F.**, Kastritis, E., ... European Myeloma Network. (2015). European Myeloma Network guidelines for the management of multiple myeloma-related complications. *Haematologica*, 100(10), 1254–66. <https://doi.org/10.3324/haematol.2014.117176>. IF 9,090.
89. Palumbo, A., Cavallo, F., **Gay, F.**, Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., ... Cavo, M. (2014). Autologous transplantation and maintenance therapy in multiple myeloma. *The New England Journal of Medicine*, 371(10), 895–905. <https://doi.org/10.1056/NEJMoa1402888>. IF 79,260.
90. Festuccia, M., Giaccone, L., **Gay, F.**, Brunello, L., Maffini, E., Ferrando, F., ... Bruno, B. (2014). Trichoderma species fungemia after high-dose chemotherapy and autologous stem cell transplantation: a case report. *Transplant Infectious Disease: An Official Journal of the Transplantation Society*, 16(4), 653–7. <https://doi.org/10.1111/tid.12245>. IF 1,869.
91. Gambella, M., Rocci, A., Passera, R., **Gay, F.**, Omede, P., Crippa, C., ... Palumbo, A. (2014). High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. *HAEMATOLOGICA*, 99(2), E14–E16. <https://doi.org/10.3324/haematol.2013.090142>. IF 9,090.
92. Rocci, A., Gambella, M., Aschero, S., Baldi, I., Trusolino, L., Cavallo, F., ..., **Gay, F.**, ... Palumbo, A. (2014). MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. *BRITISH JOURNAL OF HAEMATOLOGY*, 164(6), 841–850. <https://doi.org/10.1111/bjh.12719>. IF 5,128.
93. Caltagirone, S., Ruggeri, M., Aschero, S., Gilestro, M., Oddolo, D., **Gay, F.**, ... Omede, P. (2014). Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. *HAEMATOLOGICA*, 99(10), 1611–1617. <https://doi.org/10.3324/haematol.2014.103853>. IF 9,090.
94. Donato, F., **Gay, F.**, Bringhen, S., Troia, R., & Palumbo, A. (2014). Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. *EXPERT OPINION ON BIOLOGICAL THERAPY*, 14(8), 1127–1144. <https://doi.org/10.1517/14712598.2014.908848>. IF 3,974.
95. Bringhen, S., **Gay, F.**, Donato, F., Troia, R., Mina, R., & Palumbo, A. (2014). Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. *EXPERT OPINION ON INVESTIGATIONAL DRUGS*, 23(9), 1193–1209. <https://doi.org/10.1517/13543784.2014.920821>. IF 3,883.
96. Engelhardt, M., Terpos, E., Kleber, M., **Gay, F.**, Waesch, R., Morgan, G., ... Network, E. M. (2014). European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. *HAEMATOLOGICA*, 99(2), 232–242. <https://doi.org/10.3324/haematol.2013.099358>. IF 9,090.
97. van de Donk, N. W. C. J., Palumbo, A., Johnsen, H. E., Engelhardt, M., **Gay, F.**, Gregersen, H., ... Network, E. M. (2014). The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. *HAEMATOLOGICA*, 99(6), 984–996. <https://doi.org/10.3324/haematol.2013.100552>. IF 9,090.
98. Falco, P., Cavallo, F., Larocca, A., Rossi, D., Guglielmelli, T., Rocci, A., ... Palumbo, A. (2013). Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. *Leukemia*, 27(3), 695–701. <https://doi.org/10.1038/leu.2012.271>. IF 10,023.
99. Palumbo, A., Waage, A., Hulin, C., Beksac, M., Zweegman, S., **Gay, F.**, ... Sonneveld, P. (2013). Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. *Haematologica*, 98(1), 87–94. <https://doi.org/10.3324/haematol.2012.067058>. IF 9,090.

100. **Gay, F.**, Magarotto, V., Crippa, C., Pescosta, N., Guglielmelli, T., Cavallo, F., ... Palumbo, A. (2013). Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. *Blood*, 122(8), 1376–83. <https://doi.org/10.1182/blood-2013-02-483073>. Erratum in (2014) *Blood*, 123(24), 3843. IF 15,132.
101. **Gay, F.**, Mina, R., Troia, R., & Bringhen, S. (2013). Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. *EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY*, 9(11), 1517–1527. <https://doi.org/10.1517/17425255.2013.827169>. IF 3,151.
102. Kumar, S. K., Lacy, M. Q., Dispenzieri, A., Buadi, F. K., Hayman, S. R., Dingli, D., ..., **Gay, F.**, ... Gertz, M. A. (2012). Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. *CANCER*, 118(6), 1585–1592. <https://doi.org/10.1002/cncr.26422>. IF 6,537.
103. Bringhen, S., **Gay, F.**, Pautasso, C., Cerrato, C., Boccadoro, M., & Palumbo, A. (2012). Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. *EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY*, 8(9), 1209–1222. <https://doi.org/10.1517/17425255.2012.712685>. IF 3,151.
104. Guglielmelli, T., Bringhen, S., Rrodhe, S., **Gay, F.**, Cavallo, F., Berruti, A., ... Palumbo, A. (2011). Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. *European Journal of Cancer (Oxford, England: 1990)*, 47(6), 814–8. <https://doi.org/10.1016/j.ejca.2010.12.026>. IF 7,191.
105. Benevolo, G., Larocca, A., Gentile, M., Pregno, P., **Gay, F.**, Botto, B., ... Palumbo, A. (2011). The Efficacy and Safety of Bortezomib and Dexamethasone as a Maintenance Therapy in Patients With Advanced Multiple Myeloma Who Are Responsive to Salvage Bortezomib-Containing Regimens. *CANCER*, 117(9), 1884–1890. <https://doi.org/10.1002/cncr.25743>. IF 6,537.
106. **Gay, F.**, Larocca, A., Wijermans, P., Cavallo, F., Rossi, D., Schaafsma, R., ... Palumbo, A. (2011). Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. *Blood*, 117(11), 3025–31. <https://doi.org/10.1182/blood-2010-09-307645>. IF 15,132.
107. Bruno, B., **Gay, F.**, Boccadoro, M., & Palumbo, A. (2011). Management of myeloma: an Italian perspective. *Clinical Lymphoma, Myeloma & Leukemia*, 11 Suppl 1, S82–6. <https://doi.org/10.1016/j.clml.2011.03.026>. IF 2,308.
108. **Gay, F.**, & Palumbo, A. (2011). Management of older patients with multiple myeloma. *Blood Reviews*, 25(2), 65–73. <https://doi.org/10.1016/j.blre.2010.10.003>. IF 6,600.
109. Palumbo, A., & **Gay, F.** (2011). A new combination for advanced multiple myeloma. *The Lancet Oncology*, 12(3), 207–208. [https://doi.org/10.1016/S1470-2045\(11\)70036-5](https://doi.org/10.1016/S1470-2045(11)70036-5). IF 36,421.
110. **Gay, F.**, Hayman, S. R., Lacy, M. Q., Buadi, F., Gertz, M. A., Kumar, S., ... Rajkumar, S. V. (2010). Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. *Blood*, 115(7), 1343–1350. <https://doi.org/10.1182/blood-2009-08-239046>. IF 15,132.
111. Palumbo, A., Larocca, A., Genuardi, M., Kotwica, K., **Gay, F.**, Rossi, D., ... GIMEMA. (2010). Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*, 95(7), 1144–1149. <https://doi.org/10.3324/haematol.2009.047913>. IF 9,090.
112. **Gay, F.**, Rajkumar, S. V., Falco, P., Kumar, S., Dispenzieri, A., Petrucci, M. T., ... Palumbo, A. (2010). Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. *EUROPEAN JOURNAL OF HAEMATOLOGY*, 85(3), 200–208. <https://doi.org/10.1111/j.1600-0609.2010.01469.x>. IF 2,595.
113. **Gay, F.**, Rajkumar, S. V., Coleman, M., Kumar, S., Mark, T., Dispenzieri, A., ... Niesvizky, R. (2010). Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. *AMERICAN JOURNAL OF HEMATOLOGY*, 85(9), 664–669. <https://doi.org/10.1002/ajh.21777>. IF 5,303

114. **Gay, F.** & Palumbo, A. (2010). Multiple myeloma: management of adverse events. *Medical Oncology (Northwood, London, England)*, 27(3), 646–53. <https://doi.org/10.1007/s12032-009-9262-4>. IF 2,920.
115. Palumbo, A., **Gay, F.**, Falco, P., Crippa, C., Montefusco, V., Patriarca, F., ... Boccadoro, M. (2010). Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. *JOURNAL OF CLINICAL ONCOLOGY*, 28(5), 800–807. <https://doi.org/10.1200/JCO.2009.22.7561>. IF 26,360.
116. **Gay, F.** & Palumbo, A. (2010). Management of disease- and treatment-related complications in patients with multiple myeloma. *MEDICAL ONCOLOGY*, 27(1), 43–52. <https://doi.org/10.1007/s12032-010-9542-z>. IF 2,920. Citazioni ricevute: WoS AD 12; WoS CC 12; Sc 15.
117. Palumbo, A., & **Gay, F.** (2010). Towards a new standard of care for patients with myeloma? *The Lancet Oncology*, 11(1), 3–4. [https://doi.org/10.1016/S1470-2045\(09\)70313-4](https://doi.org/10.1016/S1470-2045(09)70313-4). IF 36,421.
118. Corso, A., Zappasodi, P., Barbarano, L., Petrucci, M. T., Palumbo, A., Caravita, T., ..., **Gay, F.** ... Lazzarino, M. (2009). Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. *Leukemia Research*, 33(9), e145–e149. <https://doi.org/10.1016/j.leukres.2009.03.015>. IF 2,319.
119. Palumbo, A., Falco, P., Falcone, A., Benevolo, G., Canepa, L., **Gay, F.** ... G, I. M. M. N. (2009). Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results. *CLINICAL LYMPHOMA & MYELOMA*, 9(2), 145–150. <https://doi.org/10.3816/CLM.2009.n.035>. IF 1,130.
120. Morabito, F., Gentile, M., Gay, F., Bringhen, S., Mazzone, C., Vigna, E., ..., **Gay, F.** ... Palumbo, A. (2009). Insights into defibrotide: an updated review. *Expert Opinion on Biological Therapy*, 9(6), 763–772. <https://doi.org/10.1517/14712590903008507>. IF 3,974.
121. Palumbo, A., & **Gay, F.** (2009). How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. *Hematology. American Society of Hematology. Education Program*, 2009(1), 566–77. <https://doi.org/10.1182/asheducation-2009.1.566>. IF 2,238.
122. Musto, P., D'Auria, F., Pietrantonio, G., Baldini, L., Bringhen, S., Caravita, T., ..., **Gay, F.** ... Palumbo, A. (2009). First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Multiple Myeloma Working Party Perspective. *CURRENT DRUG TARGETS*, 10(10), 906–922. <https://doi.org/10.2174/138945009789577936>. IF 3,112.
123. Palumbo, A., **Gay, F.**, Bringhen, S., Falcone, A., Pescosta, N., Callea, V., ... Boccadoro, M. (2008). Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, 19(6), 1160–5. <https://doi.org/10.1093/annonc/mdn018>. IF 13,930.
124. Montefusco, V., **Gay, F.**, Spina, F., Miceli, R., Maniezzo, M., Ambrosini, M. T., ... Corradini, P. (2008). Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. *LEUKEMIA & LYMPHOMA*, 49(11), 2156–2162. <https://doi.org/10.1080/10428190802483778>. IF 2,644.
125. Palumbo, A., Bringhen, S., Liberati, A. M., Caravita, T., Falcone, A., Callea, V., ... Boccadoro, M. (2008). Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. *Blood*, 112(8), 3107–14. <https://doi.org/10.1182/blood-2008-04-149427>. IF 15,132.
126. Palumbo, A., Magarotto, V., **Gay, F.**, Falco, P., Bringhen, S., & Boccadoro, M. (2008). Update on Recent Developments for Patients with Newly Diagnosed Multiple Myeloma. In Branicki, FJ and Adem, A and GhazalAswad, S and Torab, FC (Ed.), *RECENT ADVANCES IN CLINICAL ONCOLOGY* (Vol. 1138, pp. 19–21). <https://doi.org/10.1196/annals.1414.004>. IF 4,277.
127. Palumbo, A., Facon, T., Sonneveld, P., Blade, J., Offidani, M., **Gay, F.** ... Harousseau, J.-L. (2008). Thalidomide for treatment of multiple myeloma: 10 years later. *Blood*, 111(8), 3968–3977. <https://doi.org/10.1182/blood-2007-10-117457>. IF 15,132.




128. Palumbo, A., Falco, P., **Gay, F.**, Magarotto, V., Patriarca, F., Nozzoli, C., & Boccadoro, M. (2008). From cell biology to therapy: Lenalidomide in untreated multiple myeloma. *Haematologica Meeting Reports*, 2(5), 94–97. IF rivista non indicizzata.
129. Musto, P., Rossini, F., **Gay, F.**, Pitini, V., Guglielmelli, T., D'Arena, G., ... Cooperative, G. G. G. (2007). Efficacy and safety of bortezomib in patients with plasma cell leukemia. *CANCER*, 109(11), 2285–2290. <https://doi.org/10.1002/cncr.22700>. IF 6,537.
130. Palumbo, A., Bringhen, S., Falco, P., Cavallo, F., Ambrosini, M. T., Avonto, I., ..., **Gay, F.**, ... Boccadoro, M. (2007). Time to first disease progression, but not beta 2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. *CANCER*, 110(4), 824–829. <https://doi.org/10.1002/cncr.22855>. IF 6,537.
131. Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., ..., **Gay, F.**, ... Petrucci, M. T. (2007). Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA - Italian multiple myeloma network. *JOURNAL OF CLINICAL ONCOLOGY*, 25(28), 4459–4465. <https://doi.org/10.1200/JCO.2007.12.3463>. IF 26,360.
132. Falco, P., Bringhen, S., Avonto, I., **Gay, F.**, Morabito, F., Boccadoro, M., & Palumbo, A. (2007). Melphalan and its role in the management of patients with multiple myeloma. *EXPERT REVIEW OF ANTICANCER THERAPY*, 7(7), 945–957. <https://doi.org/10.1586/14737140.7.7.945>. IF 2,347.
133. Palumbo, A., Avonto, I., Bruno, B., Falcone, A., Scalzulli, P. R., Ambrosini, M. T., ..., **Gay, F.**, ... Boccadoro, M. (2006). Intermediate-dose melphalan (100 mg/m<sup>2</sup>)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma. *CLINICAL LYMPHOMA & MYELOMA*, 6(6), 475–477. <https://doi.org/10.3816/CLM.2006.n.028>. IF 1,130.
134. Palumbo, A., Falco, P., Musto, P., Rossi, G., Giuliani, N., Morabito, F., ..., **Gay, F.**, ... Boccadoro, M. (2006). New treatment strategies for elderly myeloma patients. *Haematologica Reports*, 2(7), 113–114. IF rivista non indicizzata.

## BOOK CHAPTERS

1. **Gay, F.**, Oliva, S., & Palumbo, A. (2010). Treatment of Myeloma in Transplant-Ineligible Patients. In Kumar, S (Ed.), *Multiple Myeloma* (2nd ed., Vol. 1 I2, "Emerging Cancer therapeutics", pp. 363–382). New York (US): Demos Medical Publishing. ISBN: 9781935281450. <https://doi.org/10.5003/2151-4194.1.2.363>
2. Palumbo, A., & **Gay, F.** (2009). Multiple Myeloma. In F. Cavalli, S. B. Kaye, H. H. Hansen, J. O. Armitage, & M. Piccart-Gebhart (Eds.), *Textbook of Medical Oncology* (4th ed., pp. 274–282). London (UK)–Boca Raton (FL-US): Informa Healthcare–Taylor & Francis. ISBN: 9780203092897.
3. Boccadoro, M., **Gay, F.**, Larocca, A., Magarotto, V., & Palumbo, A. (2008). Gammopatie monoclonali. In P. Corradini, R. Foa', M. Boccadoro, M. D. Cappellini, C. Carlo-Stella, M. Cattaneo, ... E. M. Pogliani (Eds.), *Manuale di Ematologia* (1st ed., pp. 183–194). Torino: Minerva Medica. ISBN: 9788877118165.

Turin, April 7 2022

Dr. Francesca Maria Gay



## Attachment B: Oral and Poster presentations (first author/presenting author/last author)

### ORAL PRESENTATIONS

1. **Gay F.** Berdeja JG, De Stefano V, .. Lin Y. Results from a meta-analysis of ciltacabtagene autoleucel compared to physician's choice of treatment in patients with relapsed or refractory multiple myeloma (2022) EMN 2022 Meeting Abstract
2. Mina R, Zamagni E, Fazio F, ...**Gay F** Efficacy of carfilzomib-based induction/consolidation with or without autologous transplant and lenalidomide or carfilzomib-lenalidomide maintenance in high-risk patients in the FORTE trial. EHA Meeting Abstract 2021
3. **Gay F.** Mina R, Rota-Scalabrini D, .. Boccadoro M Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients (ASCO 2021 Meeting Abstract)
4. **Gay F.** Musto P, Scalabrini DR... Boccadoro M. survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial Blood (2020) ASH Meeting Abstract 141 (Supplement 1)
5. Oliva S, Genuardi E, Petrucci MT, ..**Gay F.** Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial Blood (2020) ASH Meeting Abstract 491 (Supplement 1)
6. **Gay F.** Zaccaria GM, Offidani M, Vozella F, Becco P, ...Boccadoro M. Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients. Blood (2019) ASH Meeting Abstracts 134 (Supplement\_1): 605.
7. **Gay F.** C. Cerrato, M.T. Petrucci, R. Zambello, E. Rivolti, S. Ballanti, P.... M. Boccadoro Carfilzomib, Lenalidomide, Dexamethasone (KRd) With or Without Transplantation in Newly Diagnosed Myeloma Patients: Subgroup Analysis in the FORTE Trial Haematologica, 104(s2), 1 [SIE 2019 47th Congress]. Retrieved from <http://www.haematologica.org/content/104/s2>
8. **Gay F.** Cerrato C., Rota Scalabrini D., Belotti A., Galli M., Zamagni E., ..., Boccadoro M (2019). Carfilzomib Lenalidomide Dexamethasone (KRd) With or Without Transplantation in Newly Diagnosed Myeloma (FORTE Trial): Efficacy According to Risk Status. Abstract #S872, EHA 2019 24th Congress, selected for oral presentation (June 15, 2019).
9. **Gay F.** Cerrato, C., Petrucci, M. T., Zambello, R., Gamberi, B., Ballanti, S., ... Boccadoro, M. (2019). Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the forte trial. Abstract #8002 (ASCO 2019 Annual Meeting).
10. **Gay F.** Cerrato, C., Scalabrini, D. R., Galli, M., Belotti, A., Zamagni, E., ... Boccadoro, M. (2018). Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized FORTE Trial in Newly Diagnosed Multiple Myeloma (NDMM). Blood, 132(Suppl 1), Abstract #121 [ASH 2018 60th Meeting]. <https://doi.org/10.1182/BLOOD-2018-99-112093>
11. **Gay F.** Rota Scalabrini, D., Belotti, A., Oliva, S., Rambaldi, A., Zamagni, E., ... Boccadoro, M. (2018). UPDATED EFFICACY AND MRD DATA ACCORDING TO RISK-STATUS IN NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH CARFILZOMIB PLUS LENALIDOMIDE OR CYCLOPHOSPHAMIDE: RESULTS FROM THE FORTE TRIAL. HemaSphere, 2(s1), 6 [Abstract #s109, EHA 2018 23rd Congress].
12. **Gay F.** Rota Scalabrini, D., Belotti, A., Offidani, M., Petrucci, M. T., Esma, F., ... Boccadoro, M. (2017). Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned



interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM). JOURNAL OF CLINICAL ONCOLOGY, 35(15), Abstract #8003 [ASCO 2017 Annual Meeting]. [https://doi.org/10.1200/JCO.2017.35.15\\_suppl.8003](https://doi.org/10.1200/JCO.2017.35.15_suppl.8003)

13. **Gay, F.** Rota Scalabrini, D.; Belotti, A.; Offidani, M.; Tacchetti, P.; Petrucci, M. ... Boccadoro, M. (2017). CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION: PLANNED INTERIM ANALYSIS OF THE RANDOMIZED FORTE TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA. *Haematologica*, 102(s2), 143-144 [Abstract #S410, EHA 2017 22nd Congress].
14. **Gay, F.** Spadano, A., Cavo, M., Caravita, T., Canepa, L., Giuliani, N., ... Boccadoro, M. (2017). INTERIM ANALYSIS OF CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE IN THE FORTE TRIAL. *Haematologica*, 102(s3), 1 [Abstract #B001, SIE 2017 46th Congress]. Retrieved from <http://www.haematologica.org/content/102/s3>
15. **Gay, F.** Magarotto, V., Spencer, A., Di Raimondo, F., Pour, L., Scudla, V., ... Palumbo, A. (2016). UPFRONT OR RESCUE TRANSPLANT IN YOUNG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A POOLED ANALYSIS OF 529 PATIENTS. *HAEMATOLOGICA*, 101(1), 3 [Abstract #S104, EHA 2016 21st Congress].
16. **Gay, F.** D'Agostino, M., Hajek, R., Bringhen, S., Conticello, C., Gaidano, G., ... Boccadoro, M. (2016). Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. *Blood*, 128(22) [Abstract #995, ASH 2016 58th Annual Meeting].
17. **Gay, F.** Genuardi, M., Hajek, R., Petrucci, M. T., Pour, L., Falcone, A. P., ... Palumbo, A. (2015). IMPROVED OVERALL SURVIVAL WITH AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE IN NEWLY DIAGNOSED MYELOMA: A PHASE 3 TRIAL. *HAEMATOLOGICA*, 100(1), 1-2 [Abstract #S101, EHA 2015 20th Congress].
18. **Gay, F.** Oliva, S., Hajek, R., Petrucci, M. T., Ria, R., di Toritto, T. C., ... Palumbo, A. (2015). A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS. *HAEMATOLOGICA*, 100(3), 30-31 [Abstract #C056, Italian Society of Hematology (SIE) 2015 45th Congress].
19. **Gay, F.** Magarotto, V., Petrucci, M. T., Di Raimondo, F., Pour, L., Caravita, T., ... Palumbo, A. (2015). Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial. *Blood*, 126(23): Abstract #392 [ASH 2015 57th Annual Meeting].
20. **Gay, F.** Cavallo, F., Di Raimondo, F., Hardan, I., Nagler, A., Petrucci, M. T., ... Palumbo, A. (2014). IMPACT OF CONTINUOUS TREATMENT vs FIXED DURATION OF THERAPY IN NEWLY DIAGNOSED MYELOMA PATIENTS: PFS1, PFS2, OS ENDPOINTS. *HAEMATOLOGICA*, 99(1), 519 [Abstract #S1335, EHA 2014 19th Congress].
21. **Gay, F.** Cerrato, C., Hajek, R., Di Raimondo, F., Caravita, T., Falcone, A. P., ... Palumbo, A. (2014). Impact of Autologous Transplantation Vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials. *Blood*, 124(21): Abstract #198 [ASH 2014 56th Annual Meeting].
22. Palumbo A., **Gay, F.** [pres.], Spencer, A., Di Raimondo, F., Zdenek, A., Larocca, A. ...Boccadoro, M (2014). Cyclophosphamide-Lenalidomide-Dexamethasone vs ASCT, followed by maintenance with Lenalidomide-Prednisone vs Lenalidomide alone in newly diagnosed MM patients: a phase 3 randomized EMN trial. *Bone Marrow Transplantation*. 2014, April [Abstract #PH-O132, 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, 2014].
23. **Gay, F.** Hajek, R., Petrucci, M.T., Romano, A., Rocci, A., Fanin, R., ... Palumbo A (2013). Cyclophosphamide-Lenalidomide-Dexamethasone vs autologous transplant in newly diagnosed myeloma: a phase 3 trial. *Clinical Lymphoma, Myeloma & Leukemia*, 13(s1):s40 [Abstract #O-7, International Myeloma Workshop 2013 XIV Congress].
24. **Gay, F.** Hajek, R., Petrucci M.T., Romano A., Rocci, A., Fanin, R. ... Palumbo A (2013). PROLONGED PROGRESSION-FREE SURVIVAL WITH AUTOLOGOUS TRANSPLANTATION COMPARED WITH CYCLOPHOSPHAMIDE-

- LENALIDOMIDE-DEXAMETHASONE IN NEWLY DIAGNOSED MYELOMA: A PHASE 3 TRIAL. *Haematologica*, 98(s3):75 [Abstract #P043, Italian Society of Hematology (SIE) National Congress 2013]
25. **Gay, F.** Larocca, A., Mateos, M., Oliva, S., Offidani, M., Ria, R. ... Palumbo, A (2012). COMPLETE RESPONSE IS A STRONGER PREDICTOR OF SURVIVAL THAN CYTOGENETIC PROFILE AND INTERNATIONAL STAGING SYSTEM STAGE IN ELDERLY MYELOMA PATIENTS TREATED WITH BORTEZOMIB: ANALYSIS OF 771 PATIENTS. *Haematologica*, 97(s1):242 [Abstract #591, EHA 2012 17th Congress].
  26. **Gay, F.** Oliva, S., Ferrari, S., Montefusco, V., Patriarca, F., Liberati A. M. Palumbo, A. (2011). POST-TRANSPLANT LENALIDOMIDE CONSOLIDATION - MAINTENANCE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: UPDATED RESULTS OF A PHASE II TRIAL. *Haematologica*, 96(s3):8 [Abstract# C007, Italian Society of Hematology (SIE) 43rd Congress].
  27. **Gay, F.** Larocca, A., Petrucci, M. T., Musto, P., Liberati, A. M., Callea, V., ... Palumbo, A. (2010). ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF THE GISMM2001, RV-MM-PI-026 AND GIMEMA-MM-03-05 MULTICENTER ITALIAN TRIALS. *Haematologica*, 95(s3), S100 [Abstract #P075, Italian Society of Experimental Hematology XI Congress].
  28. **Gay, F.** Larocca, A., Petrucci, M. T., Musto, P., Liberati, A. M., Callea, V., ... Palumbo, A. (2010). ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS. *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*, 95(2), 236 [Abstract #0570, EHA 2010 15th Congress].
  29. Palumbo, A., Cavo, M., Bringhen, S., Cavalli, M., Patriarca, F., Rossi, D., ... Boccadoro, M. (2009). A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens. *Blood*, 114(22), Abstract #492 [ASH 2009 51st Meeting; **presented by Dr. F. Gay**].
  30. **Gay, F.** Bringhen, S., Crippa, C., Montefusco, V., Patriarca, F., Liberati, A. M., ... Palumbo, A. (2009). BORTEZOMIB-DOXORUBICIN-DEXAMETHASONE INDUCTION BEFORE AUTOLOGOUS TRANSPLANTATION, FOLLOWED BY LENALIDOMIDE CONSOLIDATION-MAINTENANCE IN UNTREATED MYELOMA PATIENTS. *Haematologica*, 94(s4), 45-46 [Abstract #C093, Italian Society of Hematology, 42nd Congress].
  31. Palumbo, A., **Gay, F.** Falcone, A., Pescosta, N., Callea, V., Caravita, T., ... Boccadoro, M. (2007). ASSOCIATION OF BORTEZOMIB, DOXORUBICIN AND DEXAMETHASONE (PAD) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS. *Haematologica*, 92(s3), 31-32 [Abstract #C-067, Italian Society of Hematology, 41st Meeting, presented by F. Gay].

## POSTER

1. D'Agostino, M, Ruggeri M, Aquino S,... **Gay F** Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial *Blood* (ASH meeting abstract 2020) 1331 (Supplement\_1).
2. Bertamini L, Capra A, Zaccaria GM..... **Gay F** High levels of circulating plasma cells predicts low rate of sustained minimal residual disease negativity in transplant eligible multiple myeloma patients treated with novel agents *HemaSphere*, 4(s1), 425 [Abstract #EP941, EHA 2020 Congress].
3. Zaccaria GM, Bertamini L, Capra A... **Gay F** S-ERMM: a simplified score to predict early relapse in newly diagnosed multiple myeloma. analysis from a pooled dataset of 2190 patients *HemaSphere*, 4(s1), 426 [Abstract #EP942, EHA 2020 Congress].

4. Oliva S, Genuardi E, Belotti A ... **Gay F** Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: results of the forte trial in newly diagnosed multiple myeloma (MM) HemaSphere, 4(s1), 436 [Abstract #EP960, EHA 2020 Congress].
5. Gay F, Bertamini L, Zaccaria GM, et al Predictors of early relapse in young multiple myeloma patients: integrated analysis of baseline features and achievement of minimal residual disease negativity HemaSphere, 4(s1), 457 [Abstract #EP999, EHA 2020 Congress].
6. Oliva S, Genuardi E, Belotti A, Frascione P, Galli M, Capra A, .... **Gay F** Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients *Blood* (ASH meeting abstract 2019) 134 (Supplement\_1): 4322.
7. Zaccaria GM, Capra A, Petrucci MT, Offidani M, Montefusco V, DI Raimondo F, .... **Gay F** **Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset** *Blood* (ASH Annual meeting 2019) 134 (Supplement\_1): 2130.
8. **Gay, F.** Dimopoulos, MA, Schjesvold, FH, Beksac, M, Hajek, R, Weisel, KC, Rajkumar, SV, MAINTENANCE THERAPY WITH THE ORAL PROTEASOME INHIBITOR (PI) IXAZOMIB SIGNIFICANTLY PROLONGS PROGRESSION-FREE SURVIVAL (PFS) POST-TRANSPLANT IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): THE PHASE 3 TOURMALINE-MM3 TRIAL, presented at the Controversies in Multiple Myeloma Meeting held in Paris, May 16-18 2019.
9. **Gay, F.** De Paoli, L., Larocca, A., Musolino, C., Genuardi, M., Montefusco, V., ... Boccadoro, M. (2018). LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS. *HemaSphere*, 2(s1), 590 [Abstract #PS1299, EHA 2018 23rd Congress].
10. **Gay, F.** Offidani, M., Günther, A., Salvini, M., Engelhardt, M., Poenisch, W., ... Gramatzki, M. (2018). CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MULTICENTER PHASE IB/II TRIAL OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP (EMNTG). *HemaSphere*, 2(s1), 230 [abstract #PF561, EHA 2018 23rd Congress].
11. **Gay, F.** Foà, R., Musto, P., Cerrato, C., Gamberi, B., Zamagni, E., ... Boccadoro, M. (2018). Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial). *Journal of Clinical Oncology*, 36(15\_suppl), Abstract #8009 [ASCO 2018 Annual Meeting]. [https://doi.org/10.1200/JCO.2018.36.15\\_suppl.8009](https://doi.org/10.1200/JCO.2018.36.15_suppl.8009)
12. **Gay, F.** Rota Scalabrini, D., Belotti, A., Galli, M., Zamagni, E., Offidani, M., ... Boccadoro, M. (2017). A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients. *Blood*, 130(Suppl 1), Abstract #4541 [ASH 2017 59th Meeting]. Retrieved from [http://www.bloodjournal.org/content/130/Suppl\\_1/4541?sso-checked=true](http://www.bloodjournal.org/content/130/Suppl_1/4541?sso-checked=true)
13. **Gay, F.** Günther, A., Offidani, M., Engelhardt, M., Schub, N., Gentili, S. (2017). A Multicenter Phase I/II EMN Study of Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma. *Clinical Lymphoma, Myeloma & Leukemia*, 17(1):e125-e126 [Abstract #PS-225, International Myeloma Workshop (IMW) 2017 XVI Congress].
14. **Gay, F.** Bringhen, S., Offidani, M., Liberati, A., Cellini, C., Magarotto, V., ... Palumbo, A. (2013). EFFICACY AND SAFETY OF 3 LENALIDOMIDE-BASED COMBINATIONS IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: RESULTS FROM THE PHASE 3 COMMUNITY BASED EMN01 TRIAL. *HAEMATOLOGICA*, 98(1), 95-96 [Abstract #P221, EHA 2013 18th Meeting].
15. **Gay, F.** Cavallo, F., Caravita, T., Cavalli, M., Nagler, A., Montefusco, V., ... Palumbo, A. (2013). Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients. *Blood*, 122(21), Abstract #2089 [ASH 2013 55th Annual Meeting].
16. **Gay, F.** Hayman, S., Buadi, F., Detweiler-Short, K., Lacy, M., Kumar, S., ... Rajkumar, V. (2010). SAFETY AND EFFICACY OF LENALIDOMIDE PLUS DEXAMETHASONE IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA

- PATIENTS 70 YEARS OF AGE AND OLDER. *Haematologica*, 95(2), 153 [Abstract #0379, EHA 2010 15th Congress].
17. **Gay, F.** Larocca, A., Wijermans, P. W., Bringhen, S., Guglielmelli, T., Schaafsma, M. R., ... Palumbo, A. (2010). Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma: Retrospective Analysis of 1175 Patients. *Blood*, 116(21): 812 [Abstract #1949, ASH 2010 52th Annual Meeting].
  18. **Gay, F.** Bringhen, S., Genuardi, M., Rossi, D., Ria, R., Romano, A., ... Palumbo, A. (2009). The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy. *Blood*, 114(22), 1495–1496 [Abstract #3887, ASH 2009 51th Annual Meeting].
  19. **Gay, F.** Falco, P., Crippa, C., Liberati, M., Patriarca, F., Cangialosi, C., ... Palumbo, A. (2009). Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients. *Blood*, 114(22), 1328 [Abstract #3419, ASH 2009 51th Annual Meeting].
  20. **Gay, F.** Hayman, S., Lacy, M. Q., Buadi, F., Gertz, M. A., Kumar, S., ... Rajkumar, S. V. (2009). Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma. *Blood*, 114(22), 1494–1495 [Abstract #3884, ASH 2009 51th Annual Meeting].
  21. **Gay, F.** Rajkumar, S. V., Falco, P., Kumar, S., Dispenzieri, A., Gertz, M., ... Palumbo, A. (2009). Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients. *Blood*, 114(22), 1123 [Abstract #2877, ASH 2009 51th Annual Meeting].
  22. **Gay, F.** Rajkumar, S. V., Jayabalan, D. S., Kumar, S., Mark, T., Dispenzieri, A., ... Niesvizky, R. (2009). Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma. *Blood*, 114(22), 1119–1120 [Abstract #2868, ASH 2009 51th Annual Meeting].

Turin, April 7 2022

Dr. Francesca Maria Gay



**Attachment C: National and International Meetings****CHAIR**

1. ESMO Guidelines: Real World Cases Webinar - Multiple Myeloma 20 July 2021
2. European Hematology Association (EHA) 26<sup>th</sup> Congress, online meeting, 11/06- 15/06, 2021.
3. 3rdth European School of Hematology (ESH) Hot to diagnose and Treat Multiple Myeloma 16-18/04/2021 (web meeting)
4. 2st Meeting of the European-Myeloma-Network (EMN), Web, 3-6/03/2021.
5. 62nd American Society of Hematology (ASH) Annual Meeting, online meeting, 2 - 8 /12/ 2020;
6. European Hematology Association (EHA) 25<sup>th</sup> Congress, online meeting, 11/06- 15/10, 2020.
7. 61st American Society of Hematology (ASH) Annual Meeting, Orlando, FL, USA 7 - 10 /12/ 2019;
8. XVII International Myeloma Workshop (IMW), Boston, USA, 12-15 /09/ 2019.
9. European Hematology Association (EHA) 24<sup>th</sup> Congress, Amsterdam, 13-16 /06/ 2019.
10. 2nd How to Diagnose and Treat Multiple Myeloma, European School of Hematology (ESH), Berlin, 5-7 /04/ 2019.
11. Korean Society of Hematology (KSH) International Conference & the 6<sup>th</sup> Annual Meeting, Seoul 14-16 /03/ 2019.
12. XVI International Myeloma Workshop (IMW) New Delhi, India, 1 -4 /03/ 2017.
13. 21st Congress of the European Hematology Association (EHA), Copenhagen, 9-12 /06/ 2016.
14. 18th Congress of the European Hematology Association (EHA), Stockholm, Svezia, 13 - 16 /06/ 2013;
15. 54st American Society of Hematology (ASH) Annual Meeting, Atlanta, GE, USA 8 -11 /12/ 2012;
16. 53st American Society of Hematology (ASH) Annual Meeting, San Diego, CA, USA 10- 13 /12/ 2011.

**INVITED SPEAKER- Selected National and international meetings**

1. Speaker 3rd Meeting of the European-Myeloma-Network (EMN), web 6-8 Apr 2022.  
*New trials under the EMN*
2. Speaker at the XVII National Meeting of the Italian Society of Experimental Hematology, March 31, 2022  
*Determinanti biologici della sustained mrd negativity nel contesto delle nuove terapie*
3. Speaker at the 48<sup>th</sup> European Blood Marrow Transplant (EBMT) annual meeting, online event 19-23 March 2022  
*Does achievement of MRD after transplant improve survival? Multiple Myeloma*
4. ESMO Congress 2021, 16/09/ 2021 (prerecorded)  
*Educational session in multiple myeloma: New treatment Strategies- CAR T cells and more*
5. Speaker at the 2021 American Society of Clinical Oncology (ASCO) annual meeting, online event 04-08 June 2021  
*Educational session "When and how to treat relapsed multiple myeloma: Does one size fit all in relapsed MM: sequencing novel agents in late relapse disease*
6. Speaker Controversies in Multiple Myeloma (COMy), WEB Meeting, 7-8/5/2021.  
(1) *maintenance approaches post-transplant*  
(2) *GSK symposium BCMA-targeted therapies: the 4th pillar in treating relapsed/refractory multiple myeloma*
7. Speaker American Association for Cancer Disease Myeloma Discovery to therapy, 27/04/2021 (web)  
*Novel therapeutics and drug resistance, Treatment of lenalidomide refractory patients*
8. Speaker 3rdth European School of Hematology (ESH) Hot to diagnose and Treat Multiple Myeloma 16-18/04/2021 (web meeting)  
*Keynote lecture: the future of MM. The Future is now, science fiction thereafter*



9. Speaker 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 14/03/2021 (web)  
Challenges in Relapse-refractory multiple myeloma - Sanofi Industry Symposium  
*Lenalidomide Refractory Patients- evidence based recommendation*  
Is the gold standard for managing transplant eligible newly-diagnosed multiple myeloma still golden? - Janseen Industry Symposium  
*Is there still a role for autologous stem cell transplantation in frontline management of patients with MM?*
10. Speaker 2nd Meeting of the European-Myeloma-Network (EMN), web 3-6/03/2021.  
(1) *Young Patients with Myeloma: First line treatment*  
(2) *Janssen Symposium. Managing patients with MM, now and in the new normal.*
11. Speaker 23<sup>rd</sup> European Multiple Myeloma Academy (EMMA) Congress, Vienna, Austria, 22-23/01/2021.  
*Management of patients with special conditions: High-risk disease including Plasma cell leukemia and extramedullary disease*
12. Speaker at the 62nd American Society of Hematology (ASH) Annual Meeting, online meeting, 2 - 8 /12/2020  
*Educational Spotlight session: How to manage common challenging situations in patients with multiple myeloma: management of patients with renal failure*  
*Scientific Workshop on immunoprofiling and minimal residual disease testing in multiple myeloma. Results from the FORTE study*
13. Speaker at the National Congress of Sociedad Espanola de Hematologia y Hemoterapia (SEHH), web, 28/10/2020  
*GSK symposium New landscape for the triple-class refractory Multiple Myeloma patients*
14. Speaker 5th European School of Hematology (ESH) Translational Research Conference Multiple Myeloma 8-11/10/2020 (web meeting)  
(1) *Meet the Expert "assessment of MRD evaluation"*  
(2) *GSK symposium Targeting BCMA: a promising target?*
15. Speaker Virtual Academic Meeting of the Mexican Society of Hematology, WEB Meeting, 17/09/2020  
*Treatment in patients with multiple myeloma: the choice of the second line, what are our options today?*
16. Speaker XVIII. National Workshop Multiple Myeloma and Annual Meeting of Czech Myeloma Group WEB Meeting, 14/09/2020  
*Treatment for high- risk multiple myeloma;*  
Amgen Symposium at the same meeting 14/09/2020  
*Reflecting Italian Real world clinical practice with carfilzomib in relapsed-refractory multiple myeloma*
17. Speaker 22<sup>nd</sup> European Multiple Myeloma Academy (EMMA) Congress, Madrid, Spain, 03-04/09/2020-web.  
*How I treat elderly patients*
18. Speaker 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 30/08-2/09/2020, Madrid, Spain (web)  
*How do I mobilize autologous stem cell after antibodies and IMiDs based induction in MM patients*  
From kilometre zero - Navigating the myeloma treatment journey - Amgen Industry Symposium  
*Off to a good start - Optimal induction regimen for transplant eligible patients*
19. Speaker Controversies in Multiple Myeloma (COMy), WEB Meeting, 14-16/5/2020.  
*Anti-CD38 antibodies-based induction prior to transplant for all? No*
20. Speaker EHA-ISHBT Hematology Tutorial on Hematological Disorders, Chandigar, India, 27-28/02/2020  
*Multiple myeloma (Web due to travel limitation for COVID-19 disease travel limitation)*
21. Speaker European Multiple Myeloma Academy (EMMA), Wien, Austria, 25/1/2020.  
*Treatment of high-risk myeloma: extramedullary disease and plasmacell leukemia*



22. Speaker HEMO, Brazilian Congress of Hematology, 6-9/11/2019, Rio de Janeiro, Brasil,  
*How to define and manage high-risk myeloma patients*  
Amgen symposium *Is it worthless to keep prescribing ASCT for myeloma?*
23. Speaker at 2nd CMWP Scientific & Educational Meeting, Istanbul, Turkey, 19/10/19.  
*Multiple Myeloma, Treatment of transplant Ineligible patients*
24. Speaker at Hematologic Malignancies, Rimini, Italia, 18 Ottobre 2019; *Multiple Myeloma, Risk factors and Criteria for treatment*
25. Speaker at 47° Congresso Nazionale SIE (Società Italiana di Ematologia), Luch Meeting, ROMA, Italia, da 7 al 8 Ottobre 2019; *Lo scenario terapeutico del Mieloma Multiplo di oggi e del futuro, L'importanza del meccanismo d'azione del carfilzomib per il beneficio clinico nel mieloma multiplo*
26. 20th European Multiple Myeloma Academy (EMMA) Congress, Madrid, Spain, 04-05/10/2019.  
*Workshop: Optimize diagnosis and monitoring in myeloma*
27. XVII International Myeloma Workshop (IMW), Boston, USA, 12-15 September 2019.  
*Should we use MRD for drug development and approval?*  
*Primary Plasma cell leukemia*
28. Highlights from past (24<sup>th</sup>) EHA, HOPE, Kolkata, India, 23-25 August 2019.  
*Optimal sequencing in relapsed/refractory myeloma*
29. European Hematology Association (EHA) 24th Congress, 14th June 2019.  
*Meet the Expert: Optimal sequencing in relapsed/refractory myeloma*
30. Controversies in Multiple Myeloma (COMy), Paris, France, 16-18/5/2019.  
(1) *Management of Special Situations: Plasma-Cell Leukemia;*  
(2) *Amgen Satellite Symposium Evolving therapeutic possibilities in multiple myeloma*
31. 2nd European School of Hematology (ESH) Meeting on How to Diagnose and Monitor Multiple Myeloma, Berlin, 5-7/04/2019.  
(1) *From Studies to Reality: A Transplant-Eligible Patient with a Non-Aggressive Relapse 24 Months after Autologous Stem-Cell Transplant Followed by Lenalidomide Maintenance.*  
(2) *Meet the expert "Stem Cell Transplantation"*
32. British Society of Hematology Annual Meeting, UK Myeloma Forum, Glasgow, United Kingdom, 1/04/2019.  
*Host and Tumor Biomarkers: A Route to Ultra-Stratification.*
33. Korean Society of Hematology International Conference & 60th Annual Meeting, European Hematology Association-Korean Society of Hematology Joint Symposium, Seoul, South Korea March 15 2019.  
(1) *Multiple Myeloma. Experimental Therapy except Monoclonal Antibodies;*  
(2) *Multiple Myeloma. Monoclonal Antibodies in the Treatment of Multiple Myeloma.*
34. European Multiple Myeloma Academy (EMMA), Vienna, Austria, 31/1/2019.  
*Diagnostic Workup in Patients with Paraproteinemia.*
35. 1° Workshop di Ematologia Neoplastica, Palermo, Italy, 25/1/2019  
*Mieloma multiplo recidivato e refrattario.*
36. International Congress "Multiple Myeloma and Related Malignancies," 4th edition, Bari, 9/11/2018.  
*Benefit And Toxicity For The Choice Of Therapy.*
37. HEMO, Brazilian Congress of Hematology, 1/11/2018, San Paolo, Brasil, Janssen symposium "Redefining the History of Multiple Myeloma".

*Optimizing Treatment in Relapsed/Refractory Multiple Myeloma Patients.*

38. International Myeloma Society (IMS) Educational workshop, 26/10/2018, Athens, Greece.

*Why Should We Use Maintenance?*

39. 17th Annual meeting of the Italian and Brazilian Association of Hematology (AIBE), Torino, Italy, 22/10/2018.

*Myeloma Therapy and Clinical Ongoing Research in Italy.*

40. 15° Italian Society of Experimental Hematology Association (SIES) Congress, Rimini, Italy, 19/10/2018, Celgene Symposium "L'immunomodulazione continua nel trattamento del mieloma multiplo".

*La terapia in recidiva.*

41. European School of Hematology (ESH) 4th International Conference on Multiple Myeloma, Mandelieu, France, 5-7/10/2018, Janssen Satellite Symposium.

*How I treat Myeloma Patients.*

42. Joint Symposium Italian Hemostasis and Thrombosis Society (SISST)-Italian Society of Hematology (SIE), Alessandria, Italy, 28/9/2018.

*Mieloma multiplo: quali novità nel trattamento.*

43. Norwegian Society of Hematology Autumn's Meeting, Oslo, Norway 25-26/9/2018.

*Multiple Myeloma: Tandem Transplant and Maintenance.*

44. Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) Educational Congress, "Il trapianto allogenico nei linfomi e nel mieloma multiplo", Udine, Italy, 20-21/09/2018.

*Multiple Myeloma: Current Indication for SCT at Diagnosis and at Relapse. The Trialist Perspective.*

45. 18th European Multiple Myeloma Academy (EMMA) Congress, Madrid, Spain, 14-15/09/2018.

*Workshop: Autodiagnose and Monitor Myeloma in 2018 (From Proteins to Molecular; From X-Ray to PET. Do We Need 24-Hour Urine?*

46. 23rd Congress of EHA (European Hematology Association), Stockholm, Sweden, 14-16 June 2018 (Janssen symposium).

*Patients' and Physicians' Perspectives in Recent Advances in the Treatment for Multiple Myeloma.*

47. Controversies in Multiple Myeloma (COMy), Paris, France, 3-5/4/2018.

*Management of Special Situations: Plasma-Cell Leukemia.*

48. 1st Meeting of the European-Myeloma-Network (EMN), Torino (Italy), 19-21/04/2018.

(1) *When to Use Novel Proteasome Inhibitors and Immunomodulatory Drugs. Haematologica 2018, 103(1), 7.*

(2) *Janssen Symposium. Practical Management Considerations on the New Therapeutic Options in Relapsed and Refractory Multiple Myeloma.*

(3) *Celgene Symposium. Practical Implications of IMiD Compound Therapy.*

49. International Myeloma Society (IMS) Educational workshop, 29-30/09/2017, Prague, Czech Republic.

*When Should We Use Maintenance?*

50. Speaker at 46° Congresso Nazionale SIE (Società Italiana di Ematologia), Luch Meeting, ROMA, Italia, da 15 al 17 Ottobre 2017; *Mieloma Multiplo, riflessioni su uno scenario complesso, dalla tattica alla strategia*

51. European Cancer Congress [ECCO] 2017, Amsterdam, 29/01/2017.

*What's New In Multiple Myeloma?*

52. Lymphoma and Myeloma 2016 Meeting, New York, 13/10/2016.

*Immunologic Approaches: CAR T, Checkpoint Inhibitors, Monoclonal Antibodies.*

53. Best of EHA, Mumbai 22-24/07/2016.

(1) *New Definition of Myeloma, Newer Staging System & Role of MRD Detection;*

- (2) *Understanding The Heterogeneity of Myeloma - A Key to Success;*  
 (3) *Immuno-Oncology, Newer MiBs And MaBs in the Treatment of Myeloma.*

25. International Myeloma Workshop (IMW) 2015 XV Congress, Rome, 23-26/09/2015).  
*How I Use Supportive Care And Palliation.*

26. Regional Congress of the Italian Society of Hematology (SIE). "Focus sul mieloma multiplo", Cagliari (Italy), 30-31-05-2014.  
*Il trattamento del mieloma su stratificazione di rischio: è oggi possibile?*

## Other meetings/Webinar/Patient Seminars

*\*when speaker is not specified, it is meant as participant*

### International

1. Speaker at the iwMyeloma 2021, Virtual Event, 25-27/03/2021
2. Speaker at the HME Debate 2021, Virtual event, 21/01/2021
3. Speaker at the HME Forum post ASH 2020 on multiple myeloma, Virtual event, 14/12/2020
4. Speaker (abstract selected for oral presentation) at 62th ASH (America Society of Hematology) Annual Meeting, online meeting 2-8/12/2020;
5. Speaker at 5<sup>th</sup> edition of the International Congress on Multiple Myeloma and related malignancies, virtual event, 6/11/2020
6. Speaker at Europe Sarclisa (web) 16/10/2020
7. Speaker at the ECHO- Empowering Change in Hematology Oncology virtual event 16/10/2020
8. Speaker at 12 Trialist Forum. European Myeloma Network, Virtual event, 4-5/10/2020
9. Speaker International Conference, Updates in Clinical Hematology, WEB Meeting, Hospital Sirio Libanes San Paolo, Brazil, 02/10/2020
10. Speaker at MyKE (Myeloma Knowledge Exchange) 2020, web meeting, Sept 24-25/09/2020;
11. Speaker in the Myeloma Meeting, University of Heidelberg, Germany, 19/09/2020
12. IMWG (international Myeloma Working group) Meeting, online event, 25-26/08/2020
13. Panelist during the Inaugural meeting on Advances in Myeloma Precursor Conditions in the 21st Century, online webinar, 20/08/2020
14. Speaker at the Janseen H3 medical Education symposium, online event, 27/08/2020
15. Speaker at the online event OL-presentation Sirio Libanes 14-15/07/2020
16. Speaker at the HME Forum post EHA 2020 on multiple myeloma, Virtual event, 16/06/2020
17. Speaker in the Webinar Italian Perspective to ensure treatment continuity for MM patients during COVID19 pandemic, 8/05/ 2020
18. Speaker for the Israelian Myeloma Working group, Tel AVIV 22-24 January 2020
19. Speaker (abstract selected for oral presentation) at 61th ASH (America Society of Hematology) Annual Meeting, Orlando, FL, USA dal 7 al 10 Dicembre 2019;
20. Speaker at 18<sup>th</sup> annual meeting of the AIBE association 9 novembre 2019, Rio de Janeiro, Brasile;
21. Speaker at 11h Trialist Forum. European Myeloma Network, Baveno (Verbania), Italia, dal 29 al 30 Settembre 2019;
22. Speaker (abstract selected for oral presentation) at European Hematology Association (EHA) 24<sup>th</sup> Congress, Amsterdam, 13-16 giugno 2019.
23. Panelist at the IMWG (international Myeloma Working group) Meeting, Amsterdam, The Netherlands, 10-12/06/ 2019;
24. Speaker (abstract selected for oral presentation) at 2019 ASCO (American Society of Hematology) Annual Meeting, Chicago, USA, 31/05- 02/06/ 2019;
25. Speaker at MyKE (Myeloma Knowledge Exchange) 2019, Madrid, Spain, 10-11/05/2019;
26. Speaker at Hematology Debate 2019, Madrid, Spain, February 7 2019.
27. Speaker at 2nd Global Summit on Hematologic Malignancies, Lisbona, Portugal, February 14-16 2019.
28. Speaker (abstract selected for oral presentation) at 60th ASH (America Society of Hematology) Annual Meeting, San Diego, CA, USA dal 1 al 4 Dicembre 2018;
29. Speaker at LACAN Hematology Summit, Buenos Aires, Argentina, 15-17 Novembre 2018;

30. Speaker at 19th Myeloma Workshop Starnberger See, Munich, Germania, 10 Novembre 2018;
31. Speaker at HEMATO EXPERTS – How I Treat MM and WM, 31 ottobre 2018, San Paolo, Brasile;
32. Speaker at 17<sup>th</sup> annual meeting of the AIBE association 23 ottobre 2018, Torino, Italy;
33. Speaker at Updates in Hematologic Malignancies: How to Manage CLL, MCL and MM, Milano, Italia, 4 Ottobre 2018;
34. Speaker at 10h Trialist Forum. European Myeloma Network, Baveno (Verbania), Italia, dal 23 al 24 Settembre 2018;
35. Speaker (abstract selected for oral presentation) at 22st Congress of EHA (European Hematology Association), Stoccolma, Svezia, dal 14 al 17 giugno 2018;
36. IMWG (international Myeloma Working group) Meeting, Stoccolma, Svezia, dal 12 al 13 giugno 2018;
37. Speaker (abstract selected for oral presentation) at 2018 ASCO (American Society of Hematology) Annual Meeting, Chicago, USA, dal 1 al 5 giugno 2018;
38. Speaker at MyKE (Myeloma Knowledge Exchange) 2018, Vienna, Austria, 27-28 Aprile 2018;
39. Speaker at European Cooperative Groop Meeting, Parigi, 12-13 Aprile 2018;
40. Speaker at 9th Investigator Research Meeting, Francoforte, Germania, dal 23 Marzo al 24 marzo 2018;
41. Riunione EMN-EMN-Italy, Amsterdam, Olanda, 22 Marzo 2018;
42. Riunione EMN-EMN-Italy, Amsterdam, Olanda, 15 Marzo 2018;
43. Speaker at 1st Global Summit on Hematologic Malignancies, Madrid, Spagna, 16-17 Febbraio 2018;
44. Speaker at Hematology Debate 2019, Roma, Italia, 7-8 Febbraio 2018;
45. 59st ASH (America Society of Hematology) Annual Meeting, Atlanta, GA, USA dal 9 al 12 Dicembre 2017;
46. Speaker at 19th Myeloma Workshop Starnberger See, Munich, Germania, 11 Novembre 2017;
47. Speaker at Multiple myeloma 2017 keeping track in a multifaceted landscape of treatment strategies, Freiburg, Germania, 25 Ottobre 2017;
48. Speaker at 9th Trialist Forum. European Myeloma Network, Baveno (Verbania), Italia, dal 24 al 25 Settembre 2017;
49. Speaker (abstract selected for oral presentation) at 22st Congress of EHA (European Hematology Association), Madrid, Spagna, dal 22 al 25 giugno 2017;
50. IMWG (international Myeloma Working group) Meeting, Madrid, Spagna, dal 20 al 21 giugno 2017;
51. Speaker (abstract selected for oral presentation) at 2017 ASCO (American Society of Hematology) Annual Meeting, Chicago, USA, dal 2 al 6 giugno 2017;
52. 8th Investigator Research Meeting, Saronno, Italia, dal 31 Marzo al 1 aprile 2017;
53. XVI International Myeloma Workshop (IMW) New Delhi, India, dal 1 al 4 marzo 2017.
54. Speaker at Opinioni a confronto in Oncologia: mieloma multiplo, Bellinzona, Svizzera, 9 Febbraio 2017;
55. Speaker at (abstract selected for oral presentation) 58st ASH (America Society of Hematology) Annual Meeting, San Diego, CA, USA dal 3 al 6 Dicembre 2016;
56. Speaker at 8th Trialist Forum. European Myeloma Network, Baveno (Verbania), Italia, dal 24 al 25 Settembre 2016;
57. Speaker at 9th Myeloma Workshop Starnberger See, Munich, Germania, dal 16 al 17 Settembre 2016;
58. Speaker (abstract selected for oral presentation) at 21st Congress of EHA (European Hematology Association), Copenhagen, Danimarca, dal 9 al 12 giugno 2016;
59. ASCO Annual Meeting, Chicago, IL, USA, dal 3 al 7 Giugno 2016;
60. Monoclonal Antibodies in multiple myeloma: an in-dept educational update, Alcada de Henares, Spagna, dal 12 al 13 Maggio 2016;
61. Speaker at Myeloma Knowledge Exchange, Berlino, Germania, dal 8 al 9 Maggio 2016;
62. 7th Investigator Research Meeting, Vienna, Austria, dal 4 al 5 Marzo 2016;
63. Speaker (abstract selected for oral presentation) at 57st ASH (America Society of Hematology) Annual Meeting, Orlando, FL, USA dal 5 al 8 Dicembre 2015;
64. Speaker at 8th Myeloma Workshop Starnberger See, Munich, Germania, dal 19 al 20 Novembre 2015;
65. Speaker (abstract selected for oral presentation) at 20th Congress of EHA (European Hematology Association), Vienna, Austria, dal 11 al 14 giugno 2015;
66. Speaker at (abstract selected for oral presentation) 56st ASH (America Society of Hematology) Annual Meeting, San Francisco, CA, USA dal 6 al 9 Dicembre 2014;
67. Speaker at 7th Myeloma Workshop Starnberger See, Munich, Germania, dal 19 al 20 Settembre 2014;
68. Speaker at 7th Trialist Forum. European Myeloma Network, Baveno (Verbania), Italia, dal 14 al 15 Settembre 2014;
69. Speaker (abstract selected for oral presentation) at 19th Congress of EHA (European Hematology Association), Milano, Italia, dal 12 al 15 giugno 2014;

70. Speaker (abstract selected for oral presentation) at 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milano, Italia, dal 30 Marzo al 2 Aprile 2014;
71. Speaker (abstract selected for oral presentation) at 55th ASH (American Society of Hematology) Annual Meeting, New Orleans, LA, USA dal 7 al 10 dicembre 2013;
72. Multiple Myeloma and Related Malignancies 2nd edition, Bari dal 7 al 9 Novembre 2013;
73. Speaker at 6th Trialist Forum. European Myeloma Network, Baveno (Verbania), Italia, dal 15 al 16 Settembre 2013;
74. Speaker (abstract selected for oral presentation) at XIV International Myeloma Workshop Kyoto, Japan, dal 3 al 7 Aprile 2013;
75. Speaker (abstract selected for oral presentation) at 17th Congress of EHA (European Hematology Association), Amsterdam, The Netherlands, dal 14 al 17 Giugno 2012;
76. Speaker at 5th Trialist Forum. European Myeloma Network, Baveno (Verbania), dal 13 al 14 Maggio 2012;
77. Speaker at What to do for Refractory Hematologic Malignancies: comparing Italian and German Experiences, Bolzano, Italia, dal 2 al 3 Novembre 2011;
78. 16th Congress of EHA (European Hematology Association), London, United Kingdom, dal 9 al 12 giugno 2011;
79. Investigator Meeting CC5013MM015, Warsaw, Poland, 18 Maggio 2011;
80. Speaker at 4th Trialist Forum. European Myeloma Network, Baveno (Verbania), Italia, dal 15 al 16 Maggio 2011;
81. 13th International Myeloma Workshop Paris, Francia, dal 3 al 6 Maggio 2011;
82. Advanced Course on Multiple Myeloma, John Hopkins University, Baltimore, MN, USA, dal 12 al 14 ottobre 2010;
83. Speaker (abstract selected for oral presentation) at 15th Congress of EHA (European Hematology Association), Barcellona, Spagna, dal 10 al 13 Giugno 2010;
84. Speaker at 3rd Trialist Forum: European Myeloma Network, Baveno, Italia, 16-17 Maggio 2010;
85. Speaker (abstract selected for oral presentation) at 51st ASH (American Society of Hematology) Annual Meeting, New Orleans, LA, USA dal 5 al 8 Dicembre 2009;
86. XII International Myeloma Workshop Washington, DC, USA, dal 26 Febbraio 2009 al 1 Marzo 2009;
87. 50th ASH (American Society of Hematology) Annual Meeting, San Francisco, CA, USA, dal 6 al 9 Dicembre 2008;
88. 34th Annual Meeting of the European Group for Blood and Marrow Transplantation, Firenze, Italia, dal 30 Marzo al 2 Aprile 2008, with final examination (4 credits);
89. European Trialist Forum: Advances in Leukemia, Lymphoma and Myeloma, Torino, Italia, 6-7 Febbraio 2008;
90. 49th American Society of Hematology Annual Meeting, Atlanta, GE, USA, dal 8 al 11 Dicembre 2007;

## National

1. Speaker at the "MM New Beginning", 25/05/21, virtual event
2. Speaker at the "Progetto educativo MM target, l'importanza dell'approccio multidisciplinare nel trattamento del paziente con mieloma multiplo recidivato-refrattario, il modello MM unit, 12/5/21, virtual event
3. Speaker at the "Building Bridges - To interconnect people", 31/03/21, virtual event
4. Speaker at the SOHO Italy- Clinical and biological School of multiple myeloma, virtual event 15-17/12/2020
5. Speaker at the Beclose 2 Hematology, percorsi di innovazione nelle patologie ematologiche (online event) 14/12/2020 (pre-recorded presentation)
6. Speaker at 12° meeting triveneto sul mieloma e gammopatie monoclonali, web, Italy, 13/11/2020
7. Speaker at Gene to Care - dalla stratificazione genetica del rischio alla terapia personalizzata nel mieloma multiplo, virtual event, 12/10/2020
8. Speaker e member of the organizing secretary and scientific committee of the "Master EMN di primo livello in management del mieloma multiplo (Edizione 2019-2020)"
9. Speaker at the HOST highlights on selected topics from Frankfurt, online event, 15/09/2020
10. Speaker at the Post EHA 2020 Virtual event, 30/06/2020.
11. Speaker and member of the organizing secretary of the Master di primo livello in management del MM, 2019-2020
12. Speaker at "Post IMW" Bologna, Italy, 19/11/19.
13. Speaker at "Master di II Livello in diagnosi e terapia dei pazienti con linfoma e Malattie linfoproliferative" Trieste, Italy, 24/10/19.
14. Speaker at "Forum in Ematologia verso il 2020" Bari, Italy, 21/10/19.
15. Speaker (abstract selected for oral presentation) at 47° Congresso Nazionale SIE (Società Italiana di Ematologia), ROMA, Italia, da 7 al 8 Ottobre 2019;
16. Speaker at Hema FORUM, "Per costruire insieme l'ematologia di domani", Milano, Italy, April 5 2019.
17. Board for the treatment of Young Myeloma Patients; European Myeloma Network (EMN), Bologna, Italy, February 14 2019.
18. Speaker at Immunotalk Mieloma Multiplo, Milano, Italia, 5 Febbraio 2019 with final examination (ECM);



19. Speaker at Mieloma 3.0 risultati ottenuti e obiettivi futuri, Milano, Italia, 21-22 gennaio 2019 e 3-4 Aprile 2019, ECM.
20. Investigator meeting EMN18, Roma, Italia, 15-16 gennaio 2019;
21. Tavola Rotonda PRIMO, Torino 9 Ottobre 2018;
22. Corso ALS, Torino, Italia, 3-4 Ottobre 2018 with final examination (ECM);
23. Immediate Life Supprt , Torino, Italia, 11 maggio 2018, with final examination (ECM);
24. Riunione EMN-Italy, Bologna, Italia, 12 Febbraio 2018;
25. Speaker at Convegno “il paziente ematologico complicato” Brescia, Italia, 1 Dicembre 2017;
26. Speaker at Convegno “le terapia del mieloma multiplo: uno scenario in continua evoluzione”, Bologna, Italia, 27 Novembre 2017;
27. Convegno “Il mieloma multiplo, un anno di cambiamenti”, Torino, Italia, il 16 Novembre 2017;
28. Speaker at Presentazione nell’ambito del programma “Hematology University 2017”, Milano, Italia, il 10 Novembre 2017;
29. Speaker at Convegno “La quadreria dell’Ematologia”, Pesaro, Italia, il7 Novembre 2017;
30. Speaker (abstract selected for oral presentation) at 46° Congresso Nazionale SIE (Società Italiana di Ematologia), ROMA, Italia, da 15 al 17 Ottobre 2017;
31. Speaker at Conferenza “Il Mieloma: recenti acquisizioni”, Torino, Italia, il 16 giugno 2017;
32. Speaker at A Closer look at immuno-oncology in multiple myeloma, Napoli, Italia, dal 26 al 27 maggio 2017;
33. Basil Life Support (BLS), Torino, Italia, 5 aprile 2017; with final examination (ECM);
34. Speaker at Progressi in Ematologia, I giovani come protagonisti, Napoli, Italia, dal 24 al 25 marzo 2017;
35. Speaker at Meeting Mieloma, Torino, Italia, 13 gennaio 2017;
36. Speaker at Sky Forum: nuovi scenari terapeutici, Pollenzo, Italia dal 24 al 25 novembre 2016;
37. La nuova era degli anticorpi monoclonali nel trattamento del mieloma multiplo, Napoli, Italia, 21 novembre 2016;
38. Speaker at Under 40 in Hematology 2016, Villafranca di Verona, Italia, 17 Novembre 2016;
39. Speaker at 6th International Palermo Conference on Innovative therapies for lymphoid malignancies, Palermo, Italia, dal 10 al 12 novembre 2017;
40. Speaker at Nuovo cinema ematologia: the directors cut, Pesaro, 8 novembre 2016, without final examination (1 ECM credit);
41. Speaker at Giornate ematologiche vicentine, VII Edizione, 11 ottobre 2016;
42. Corso teorico pratico nella gestione ottimale del paziente anziano affetto da neoplasie ematologiche, Torino, dal 3 al 4 ottobre 2016; with final examination (19 ECM credits);
43. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italia, dal 28 al 30 Settembre 2016;
44. Speaker at Mieloma Multiplo scenari in evoluzione, Torino, Italia, 20 settembre 2016;
45. Terapia antifungina: confronto con gli esperti. Necrotizing Enterocolitis (NEC): approccio diagnostico e terapeutico, Torino, il 25 Maggio 2016; with final examination (3,5 credits);
46. Speaker at FORUM M 2016, Torino, Italia, dal 13 al 14 Aprile;
47. Speaker at Under 40 in Hematology, Simposio “Gli anticorpi monoclonali nel mieloma multiplo: l’inizio di una nuova era, Villafranca di Verona, Italia, 13 Novembre 2015;
48. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italia, dal 19 al 21 Ottobre 2015;
49. Speaker (abstract selected for oral presentation) at 45° Congresso Nazionale SIE (Società Italiana di Ematologia), Firenze, Italia, da 4 al 5 Ottobre 2015;
50. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italia, dal 27 al 28 Settembre 2015;
51. Speaker at XXIII Edizione corso Cefar Le Proteine: dal laboratorio alla Clinica, Bologna, Italia, 5 Maggio 2015;
52. Elementi di statistica per l’impostazione di un protocollo di studio in onco-ematologia, Roma, Italia, 17 Dicembre 2014;
53. Speaker at HemaExcellence: la comunicazione efficace in ematologia, Torino, Italia, dal 20 al 21 Novembre 2014;
54. Speaker at Under 40 in Hematology 2014, Roma, Italia, dal 13 al 14 Novembre 2014;
55. Speaker at Innovazione nella gestione del Mieloma Multiplo, Milano, Italia, 6 Novembre 2014;
56. Speaker at Novità nei Linfomi Aggressivi e nella Leucemia Linfoblastica Acuta, Torino, Italia, 27 Ottobre 2014;
57. Speaker at Appropriata di utilizzo di Bendamustina nel mieloma multiplo, Torino, Italia, 24 Ottobre 2014;
58. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italia, dal 6 al 8 Ottobre 2014;
59. Speaker at Effective Cancer Therapy through immunomodulation, Milano, Italia, dal 29 al 30 Settembre 2014;
60. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italia, il 17 Giugno 2014;



61. Investigator meeting for protocol IST 1097-03, Milano, Italia, 15 Giugno 2014;
62. Speaker at Progetto MOVE (mozobil value evidence), Torino, Italia, 17 Gennaio 2014;
63. Speaker at Under 40 in Hematology 2013, Torino, Italia, dal 14 al 15 Novembre 2013;
64. Speaker at Rapid Fire in Hematology, Esperienze Cliniche a confronto sul mieloma multiplo, Milano, Italia, 26 Giugno 2013;
65. Speaker at Highlights from IMW 2013, Bologna, Italia, 28 Maggio 2013;
66. Advance Cardiovascular Life Support (ACLS) Corso Provider, Torino, Italia, 9 e 10 Maggio 2013;
67. Speaker at Grandangolo in Ematologia, selezione ragionata dei più recenti dati scientifici, III edizione, Milano, Italia, dal 19 al 20 Novembre 2012;
68. Speaker at Under 40 in Hematology 2013, Napoli, Italia, dal 15 al 16 Novembre 2012;
69. Speaker at Attuali conoscenze e prospettive future dell'approccio sequenziale, con mantenimento e/o consolidamento postinduzione, alla terapia delle neoplasie ematologiche, Bolzano, Italia, 30 Ottobre 2012;
70. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italia, dal 18 al 19 Settembre 2012;
71. Il Processo di accreditamento all'eccellenza Jacie e la normativa ISO 9001:2008: il trapianto autologo e lo scongelamento delle sacche criopreservate, Torino, Italia, dal 12 al 13 Settembre 2012, with final examination;
72. Speaker at La gestione del paziente anziano nelle neoplasie ematologiche, Milano, Italia, 28 Giugno 2012;
73. Speaker at Rapid Fire in Hematology: esperienze cliniche a confronto sul mieloma multiplo, Milano, Italia, 29 Maggio 2012;
74. Progetto Risk Management e l'errore in terapia, corso FAD Regione Piemonte, Torino, Italia, 26 Febbraio 2012 (ECM);
75. Speaker at Grandangolo in Ematologia, selezione ragionata dei più recenti dati scientifici, II edizione, Milano, Italia, dal 14 al 15 Novembre 2011;
76. Speaker (abstract selected for oral presentation) at 43° Congresso Nazionale SIE (Società Italiana di Ematologia), Napoli, Italia, da 16 al 19 ottobre 2011 (ECM);
77. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italia, dal 27 al 28 Settembre 2011;
78. Speaker at Tavola Rotonda, Roma, Italia, 9 Settembre 2011;
79. XI Congresso Nazionale SIES (Società Italiana di Ematologia Sperimentale), Torino, Italia, dal 6 al 8 ottobre 2010;
80. Highlights from IMW and EHA, Torino, Italia, 6 Ottobre 2010;
81. Speaker at Il mieloma multiplo oggi. La pratica clinica con i nuovi agenti, Torino, 5 Ottobre 2010 (ECM);
82. Speaker at Neoplasie Ematologiche dell'Anziano e del paziente fragile, Torino 27 e 28 Settembre 2010;
83. Immediate Life Support -ILS, Torino, Italia, il 14 maggio 2010, in qualità di discente (ECM);
84. Multiple Myeloma Debates 2010, Roma, Italia, 28-29 Gennaio 2010;
85. Speaker at I Approccio alla terapia del Mieloma nell'era dei nuovi farmaci, Padova, Italia, 19-20 Novembre 2009;
86. Speaker (abstract selected for oral presentation) at 42° Congresso Nazionale SIE (Società Italiana di Ematologia), Milano, Italia, da 18 al 20 Ottobre 2009;
87. Speaker at La terapia del mieloma multiplo, esperienze a confronto, Bolzano, Italia, il 18 e 19 aprile 2008 (ECM);
88. Speaker (abstract selected for oral presentation) at 41° Congresso Nazionale SIE (Società Italiana di Ematologia), Bologna, Italia, dal 14 al 17 ottobre 2007;
89. Corso "Mielodisplasie: diagnosi e classificazione", Torino, 21 Giugno 2007;
90. Corso "How to treat: uso dei fattori di crescita in onco-ematologia", Torino, 12 Aprile 2007;
91. Corso "Percorsi diagnostici-terapeutici nelle sindromi mieloproliferative croniche (SMPC)", Torino, 25 Gennaio 2007;
92. 2° Corso residenziale: Trapianto di Cellule Staminali emopoietiche, Firenze, dal 28 al 31 maggio 2006;
93. Advanced Trauma Life Support -ATLS Student Course of the American College of Surgeons, Dipartimento di Discipline Medico-Chirurgiche, Università di Torino, Torino, dal 21 al 27 ottobre e il 2 novembre 2004;
94. PHTLS Advances Provider, Dipartimento di Discipline Medico-Chirurgiche, Università di Torino, Torino, 6-7 Aprile 2001 in qualità di partecipante, durante il corso di studi in medicina.

## SPEAKER – PATIENT SEMINAR

1. Collaborative Seminar, Myeloma Patients, Croatian Association with support of International Myeloma Foundation, Opatjia, Croatia, 26/10/2019.
2. Collaborative Seminar, Myeloma Patients, Italian Association Against Leukemia, Lymphomas and Myeloma (AIL), Torino, Italy, 16/02/2018.
3. 2ª Conferenza Nazionale sulle neoplasie ematologiche [2nd National Conference on Hematologic Neoplasms, Rome, 11/05/2017.

4. Collaborative Seminar, Myeloma Patients, Italian Association Against Leukaemia, Lymphomas and Myeloma (AIL), Milano, Italy, 27/09/2014.

Turin, April 7 2022

Dr. Francesca Maria Gay

A handwritten signature in blue ink, appearing to read "fmg", written over a faint horizontal line.